Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
fgf2,protein,,fgf2,uniprot,q92756,plasma membrane,go:0005886,ras,protein,,ras,uniprot,q92756,plasma membrane,go:0005886,positive,d,induces,,,,,,['108'],nan,nan,fgf2 induces sustained activation of the ras—erk pathway and inhibits tgf-β1-induced emt.,pmc4440819,1,100,40,1,140
nras,protein,,nras,uniprot,q92539,plasma membrane,go:0005886,ras,protein,,ras,uniprot,q92538,plasma membrane,go:0005886,positive,d,prenylation,,,,,human,['176'],nan,nan,"initial attempts to target nras were focused on the inhibition of its membrane association, as a result of a post-translational prenylation; membrane association of ras is required for activation of downstream effectors [248]. this pharmacological strategy led to the development of many potent peptidomimetic farnesyltransferase inhibitors (ftis), which showed an excellent efficacy in preclinical models, albeit restricted to tumors bearing the hras mutation [249,250]. however, kras and nras, in respect with hras, undergo an additional step of geranylgeranylation after farnesylation, which retains their membrane association, thus making ftis useless on tumors harboring kras and nras mutations [72,251]. recently, the development of new substrates for the farnesyltransferase that prevents the alternative prenylation by geranylgeranyltransferase has successfully mislocalized oncogenic kras in vitro, raising new hopes for direct druggability of ras family members [252].",pmc6472057,1,100,40,1,140
crebbp,protein,,crebbp,uniprot,q92676,nucleus,go:0005739,kras,protein,,kras,uniprot,p19046,plasma membrane,go:0005886,positive,d,acetylation,switch ii domain,,b-cell,,human,['37'],nan,nan,"prompted by the observation that crebbp mutations frequently co-occur with ras pathway activating mutations, including kras, nras, ptpn11 and flt3,18 we investigated the influence of crebbp knockdown on ras signaling. both cell lines and primagraft all cells, with different ras pathway mutations, showed increased levels of p-erk after crebbp knockdown, suggesting that crebbp attenuation enhances ras signaling. we show that kras is directly acetylated by crebbp, a secondary modification shown to have a negative regulatory effect on ras activity by altering conformational stability of the switch ii domain and thus interaction with guanine nucleotide exchange factors.37 the link we have identified between mutations in epigenetic modifiers such as crebbp and enhanced oncogenic signaling is supported by a recent study in early thymocyte precursor all which found that inactivation of the methyltransferase, ezh2, co-operates with mutant ras to induce hyperactive cytokine signaling, principally through stat3, and was associated with a reduced sensitivity to jak inhibitors.38 further to this, inactivation of another methyltransferase, suz12, has also been shown to co-operate with ras signaling in a number of solid tumors, acting here to enhance downstream oncogenic ras transcriptional signatures.39 here, we show that, despite an enhanced ras pathway activation in crebbp attenuated all cells, sensitivity to meki was retained, which may have important clinical implications. our group has recently reported on the preclinical evaluation of the meki, selumetinib, and demonstrated significant differential sensitivity in ras pathway-mutated all compared to all without ras mutations, both in vitro and in an orthotopic xenograft model engrafted with primary all cells.23,40 clinical trials of selumetinib for relapsed ras pathway mutated all cases are underway, and the data presented here suggest that patients with co-occurring crebbp and ras mutations might still be good candidates for meki therapy.",pmc5395114,1,100,40,1,140
sirt1,protein,,sirt1,uniprot,p07088,cytoplasm,go:0005886,erk,protein,,mapk3,uniprot,p00177,cytoplasm,go:0005886,positive,d,expression,,,b-cell,,mouse,['133'],nan,nan,"the expressions of p-erk, p-jnk, and p-p38 at 1 day after brain injury were shown in fig. 4b. when the resveratrol-treated group significantly elevated the sirt1 expression (p < 0.01; fig. 3b), p-erk expression was markedly increased and p-jnk/p-p38 mapk expressions were reduced (p < 0.05 for p-erk, p < 0.01 for p-jnk and p-p38mapk; fig. 4b), as compared to the treatment with dmso in mice after brain injury. the results indicated that sirt1 mediated the expression of erk, jnk, and p-38mapk pathways after mechanical brain injury in vivo.",pmc5372348,1,100,40,1,140
da-raf,protein,,,uniprot,,,go:0005886,ras,protein,,,uniprot,,,go:0005886,positive,d,binding,,rle,epithelial-like,,mouse,['109'],nan,nan,"(a) induction of the binding of da-raf to ras by tgf-β1 stimulation. the binding was analyzed by a coimmunoprecipitation assay. rle cells were treated with 0.5 ng/ml tgf-β1 for 5 min. da-raf was immunoprecipitated with anti-da-raf pab, and coprecipitated ras was detected by immunoblotting with pan-ras mab. (b) elevation of the phosphorylation levels of mek and erk by da-raf knockdown. rle cells were transfected with daraf sirna1 as well as the control sirna and treated with 0.5 ng/ml tgf-β1 for the indicated time. the levels of mek, p-mek, erk, p-erk, da-raf, a-raf, and β-tubulin were analyzed by immunoblotting. the relative intensities of p-mek1/2 and p-erk1/2 bands are indicated under their blots. (c) recovery of daraf sirna-blocked αsma expression with u0126. rle cells were transfected with daraf sirna1 or sirna2 and then treated with 2 or 5 μm u0126 and 0.5 ng/ml tgf-β1 for 48 h. the level of αsma, as well as β-tubulin as a standard, was analyzed by immunoblotting. (d) recovery of daraf sirna-impaired αsma expressing cells with u0126. rle cells were transfected with daraf sirna1 or sirna2 and then treated with 5 μm u0126 and 0.5 ng/ml tgf-β1 for 48 h. αsma expression (red) and nuclei (blue) were detected. scale bar, 50 μm. (e) the ratio of αsma-expressing cells in the analysis of (d). the values are means ± sd of 3 independent experiments. *, p < 0.05; **, p < 0.01; #, p > 0.05 (not significant) by t test.",pmc4440819,1,100,40,1,140
nsd1,protein,,nsd1,uniprot,q92477,nucleus,go:0005739,egfr,protein,,egfr,uniprot,p00843,plasma membrane,go:0005886,positive,d,activated,,dermal fibroblasts,fibroblasts,skin,human,['124'],nan,nan,the aim of the current study was therefore to identify downstream effectors of nsd1 and to map these effectors in signaling pathways associated with growth. genome-wide mrna expression profiles of dermal fibroblasts from sos patients with a confirmed nsd1 abnormality were compared to expression patterns in age and sex-matched controls.,pmc3498325,1,100,40,1,140
shp2,protein,ptpn11,ptpn11,uniprot,p01730,cytoplasm,go:0005886,ras,protein,ras,ras,uniprot,q07817,plasma membrane,go:0005739,positive,d,binds,e76k,,b-cell,,mouse,['102'],nan,nan,"shp2 encoded by the ptpn11 gene is a member of the protein tyrosine phosphatase family and is highly expressed in hematopoietic cells. despite its role in protein dephosphorylation, shp2 plays an overall positive role on cell signaling pathways, including ras and jak–stat pathways. while the mechanism is not clear, postulated targets of shp2 include ras gap binding sites on rtks or key tyrosyl residues on sprouty proteins, which inhibit the pathway and more recent evidence implicates a role in increasing production of reactive oxygen species, which hypersensitizes cytokine signaling (41). somatic mutations of ptpn11 are common in juvenile myelomonocytic leukemia where they occur in around 35% of cases but are also found in all at frequencies between 2 and 10% (10, 14, 15, 19, 42). mutations are usually heterozygote, missense, gain of function mutations sited in the sh2 or phosphatase regions of the protein. in mouse models, ptpn11 mutations cause a myeloproliferative disorder (mpd) but a more recent study showed that the ptpn11 e76k mutation was clearly sufficient to induce acute leukemia and this residue is commonly mutated in all (43). the e76k mice leukemias were associated with centrosome amplification and aneuploidy, which is highly relevant given the predominance of ptpn11 mutations in hyperdiploid all cases.",pmc4067595,1,100,40,1,140
nsd1,protein,,nsd1,uniprot,q92535,nucleus,go:0005734,mapk,protein,,mapk,uniprot,q03962,plasma membrane,go:0005886,positive,d,binds,,,,,human,['129'],nan,nan,"the first line of evidence linking nsd1 to deregulated mapk/erk signalling was derived from the pathway analysis. given the established role of nsd1 in ra signalling, we hypothesized that the effects on gene expression and pathway analysis between sos and control would be more pronounced after treatment with ra. indeed, differences in gene expression and pathway analysis became more pronounced after ra treatment in support of our hypothesis. this might be due to an increase in fold change of the genes in the mapk pathway after ra treatment. however such an effect was not seen in the phosphorylation studies. an explanation for this difference might be the 48 hour period of stimulation with ra, which is sufficient to detect differences on an mrna level, but may be too short to reflect differences at a protein level.",pmc3498325,1,100,40,1,140
sb203580,protein,,,uniprot,q96777,plasma membrane,go:0005886,p38,protein,,,uniprot,p00736,plasma membrane,go:0005886,positive,d,inhibits,,,,,vein,['134'],nan,nan,"the effects of inhibitors u0126, sp600125, and sb203580 on erk, jnk, and p38 activation. a u0126, sp600125, and sb203580 (10 μm) significantly inhibited erk, jnk, and p38mapk activation respectively in vitro. n = 6/group, **p < 0.01 vs. the dmso group. b u0126 (200 μm), sp600125, and sb203580 (100 μm) significantly inhibited erk, jnk, and p38mapk activation respectively around the lesion site in vivo. n = 6/group, **p < 0.01 vs. the dmso group",pmc5372348,1,100,40,1,140
egfr-ras-erk,signalingpathway,,,,,plasma membrane,go:0005886,ras,protein,,ras,uniprot,q92679,plasma membrane,go:0005886,positive,d,activates,,,stem cell,colon,human,['87'],nan,nan,"we report, for the first time, how normal tissue organoids respond to inhibitors targeting the egfr-ras-erk pathway. intriguingly, drug effects were almost identical in normal organoids and patient-derived crc organoids when wt for ras. this may imply that the sensitivity of ras wt colon cancer for egfri is not an acquired oncogene-addiction, but merely represents the dependency of normal colon (stem) cells on egfr signaling activity (wong et al., 2012). indeed, normal organoids from the human colon consist predominantly of proliferative stem and progenitor cells due to the wnt ligands in the culture medium. therefore, the observed toxicity in the normal organoids may very well be most representative for direct effects on the stem cell compartments of the normal colon. indeed, one of the direct side effects of anti-egfr monotherapy is diarrhea (miroddi et al., 2015). in analogy to drug responses with wt ras, normal organoids harboring a crispr-introduced oncogenic kras mutation showed resistance profiles towards targeted therapies that closely resemble those of ras mutant crc organoids, again underscoring the dominance of the ras mutational status on drug response.",pmc5127645,1,100,40,1,140
mir-181a,noncodingrna,mirna,mir181a,mirbase,mir-181a,cytoplasm,go:0005739,ras,protein,gtpase,ras,uniprot,q04632,plasma membrane,go:0005886,negative,d,inhibits,,aml,hematopoietic stem/progenitor,bone marrow,human,['57'],nan,nan,delivery of synthetic mir-181a mimic by transferrin (tf)-conjugated nanoparticles (np) enhanced mir-181a levels and inhibited ras-dependent signaling pathways in aml,pmc5312311,1,100,40,1,140
fgf19,protein,,fgf19,uniprot,q9h2e6,plasma membrane,go:0005886,mapk,protein,,,uniprot,mapk,plasma membrane,go:0005886,positive,d,binds,,,b-cell,,vein,['125'],nan,nan,"the kegg mapk pathway consists of 781 probe sets and the go mapkkk cascade contains 433 probe sets. we determined the contribution of each of these probe sets to the differential expression of the mapk pathway in sos versus controls after ra treatment. the 50 most influential probe sets are shown in figure 1. the probe set for fgf13 contributed strongly to the differential expression of the mapk pathway and mapkkk cascade. fgf13 was the most down regulated gene in sos after ra-treatment (fold change 13.5), although this down regulation did not reach significance after correction for multiple testing (p = 0.18). besides fgf13 also fgf4, fgf6, fgf18, fgf19 and the fgfr2 contributed strongly to the differential expression of the mapk pathway. the signature of the fgf-signaling pathway as observed in the kegg pathway analysis was less clear in the go mapkkk pathway analysis.",pmc3498325,1,100,40,1,140
flt3,protein,receptor,flt3,uniprot,p00787,plasma membrane,go:0005886,ras,protein,,,uniprot,ras,cytoskeleton,go:0005929,positive,d,constitutively activates,,,b-cell,,human,['193'],nan,nan,"although ras gene mutations frequently co-occur in all, we showed here that flt3 mutations often occurred independently of other mutations (78% cases) in iamp21-all. furthermore, we identified a significantly higher incidence of flt3-itd compared with high hyperdiploid and b-other all, in which substitutions and indels were common. the mutated flt3 receptor constitutively activates a number of downstream signalling pathways implicated in leukaemogenesis (ras/raf/erk, pi3k/akt/mtor and jak/stat5) (supplementary figure 7).34, 35 despite the transcript expression from the flt3 mutant and normal alleles, perk expression was negative in a patient with flt3-itd at 4% vaf. this observation may be a reflection of the lack of sensitivity of the assay or suggest activation of an alternative pathway. considering flt3-itd has been associated with jak/stat pathway activation and is frequent in ph-like all, in which patients show a high incidence of tyrosine kinase- and cytokine-signalling abnormalities, jak/stat pathway activation and share a similar gene expression profile to iamp21-all, the mutant flt3 receptor may have a specific biological role in iamp21-all development.6, 9, 35 therapeutic inhibitors are currently being considered for the treatment of all patients with jak/stat pathway deregulation or flt3-itd acute myeloid leukaemia (aml), although the mutation must be present in the major clone or overexpressed (in relation to the wild-type allele) in order to target the majority of the leukaemic cells. although flt3-itd had an average vaf of 9% in iamp21-all, this was not reflected in the transcript expression ratio of wild-type to mutant allele in iamp21-all patients. the leukaemogenic potency and biological function of subclonal flt3-itd alleles that are overexpressed requires further investigation in order to explore the role of this abnormality in iamp21-all and assess the utility of such novel targeted therapies in the treatment of this disease.",pmc5017527,1,100,40,1,140
gimatecan,drug,,,uniprot,,,,akt,protein,,akt1,uniprot,p13889,plasma membrane,go:0005886,negative,d,binds,,,,,human,['105'],nan,nan,gimatecan exerts antitumor activity via akt and mapk signaling pathways in vitro,pmc5729429,1,100,40,1,140
grb2,protein,,grb2,uniprot,q02937,plasma membrane,go:0005886,ras,protein,,ras,uniprot,q04906,plasma membrane,go:0005886,positive,d,binds,,,epithelial-like,,human,['101'],nan,nan,"activation of a rtk stimulates autophosphorylation of its intracellular sh2 domain that recruits growth factor receptor-bound protein 2 (grb2), which serves to localize gefs to the membrane to initiate ras to exchange gdp for gtp. ras then induces raf activation by phosphorylation at specific serine residues resulting in the formation of raf homo or hetero dimers. all four isoforms of ras are able to activate all three members of the raf gene family (a raf, b raf, raf-1). raf subsequently activates mek1/2, which display restricted substrate specificity for erk1/2. erk is a potent kinase with a diverse range of both nuclear and cytoplasmic substrates. it regulates gene expression by phosphorylating numerous transcription factors including elk1. the ras/raf/mek/erk pathway (now abbreviated to ras pathway) is also implicated in the regulation of apoptosis by enhancing gene expression of pro-survival bcl-2 family proteins and targeting anti-apoptotic proteins for proteasomal degradation (5). in addition to raf/mek/erk, ras generates signal output via numerous other effector pathways, including pi3k/akt/mtor and ralgef/ral. cross talk between ras and the pi3k pathway is of particular importance given their prominent role in the regulation of cell growth and survival (2, 6–8).",pmc4067595,1,100,40,1,140
hdac,enzyme,histone deacetylase,hda1,uniprot,q92579,nucleus,go:0005739,p53,protein,tumor suppressor,tp53,uniprot,q04672,nucleus,go:0005739,positive,d,upregulation,,,tumor,,human,['24'],nan,nan,"the mechanism of synergistic activity of hdac inhibitor with chemotherapy is poorly understood. several mechanisms have been proposed, including upregulation of tumor suppressor genes like p53, as well as inhibition of the aggresome (condorelli et al., 2008; mishima et al., 2015). aberrations in the transcriptome of tumor cells are often controlled by chromatin remodeling and histone modifications (glozak and seto, 2007; hess‐stumpp, 2005). hdacs are often inappropriately expressed in cancer cells, with contentious roles in the development of oncogenesis. for instance, class ii hdacs have been shown to repress oncogenes, and the reduced expression of hdac5 and hdac10 favored malignant progression in nsclc (osada et al., 2004). on the contrary, high expression of hdac1 has been linked with poor prognosis in patients with lung adenocarcinoma (minamiya et al., 2011). however, which hdacs are coregulated to augment cytotoxicity to cancer cells, particularly here in lung scc tumors, remains elusive. we propose that belinostat synergizes cisplatin in platinum‐resistant scc cells through upregulation of genes that regulate ubiquitin‐mediated proteasomal degradation leading to disruptions of key survival signaling molecules.",pmc5537703,1,100,40,1,140
hdac,protein,enzyme,hdactr1,uniprot,p00789,nucleus,go:0005886,p53,protein,tumor suppressor,tp53,uniprot,q05214,nucleus,go:0005886,positive,d,phosphorylation,serine 18,"h2066, sw900, h2170, calu-1",epithelial,lung,human,['20'],nan,nan,"hdac inhibitors are epigenetic modulators that often induce growth inhibition in cancer cells. to investigate the antitumor mechanisms in the context of lung scc, we examined the transcriptomic and kinomic changes in belinostat‐treated cells. gene expression profiling was conducted to compare the significantly altered genes after exposure to belinostat. however, transcriptomic analyses offered little insight into the mechanism of action of belinostat, as gene ontology and pathway enrichment analyses could not identify differentially regulated signaling pathway across the belinostat‐sensitive (h2066, sw900, h2170, and calu‐1) and belinostat‐resistant (h226, h596, chago‐k‐1, and h1869) cells (data not shown).",pmc5537703,1,100,40,1,140
p70s6k-ca,protein,,,uniprot,,plasma membrane,go:0005886,rps6,protein,,,uniprot,,plasma membrane,go:0005886,positive,d,phosphorylation,,8505 c,b-cell,,human,['116'],nan,nan,"taken together, our data indicates a role for phospho-rps6 in mediating sensitivity and resistance to the combined inhibition of src and the mapk pathway. to test this hypothesis, we expressed a doxycycline inducible, constitutively active, p70s6k-e389-δct (p70s6k-ca), construct into the braf-mutant and ras-mutant dasatinib-intrinsically resistant cell lines, 8505 c and c643, respectively25,26. the addition of doxycycline induced the expression of p70s6k-ca (fig. 4a). expression of p70s6k-ca was able to partially rescue the inhibition of rps6 phosphorylation in the presence of the combination therapy, as we observed a 2-fold to 5-fold attenuation in the reduction in rps6 phosphorylation when treating with the combination therapy, in comparison to the controls. (fig. 4a and s4a). importantly, doxycycline treatment alone does not impact the inhibition of s6 phosphoryaltion (figure s4c). therefore, we next analyzed the ability of p70s6k-ca to prevent a reduction in clonogenic growth in response to either single agent (trametinib or dasatinib) or the combination. despite a rescue in rps6 phosphorylation, expression of p70s6k-ca was unable to rescue the growth inhibitory effects of the combination therapy or either single agent alone (fig. 4b and s4b).",pmc5833015,1,100,40,1,140
araf,protein,,araf,uniprot,q92577,cytoplasm,go:0005739,braf,protein,,braf,uniprot,q96674,cytoplasm,go:0005739,negative,d,binds,,homel-a1,melanoma,skin,human,['54'],nan,nan,"5 × 104 of homel-a1 or homel-l1 cells were transfected with 50 pmol sirnas (ambion) using 5 μl lipofectaminetm 2000 (invitrogen) in 1 ml opti-mem i (invitrogen) per well in 12-well plates. the following sirnas were used: pooled duplex 1 sense, 5′- ggagcuccuucaucuccaatt-3′ and duplex 2 sense, 5′- cgacuucugccuuaaguuutt-3′ for araf; pooled duplex 1 sense, 5′-ccacaucauugagaccaaatt-3′; duplex 2 sense, 5′-caauagaaccugucaauautt-3′ and duplex 3 sense, 5′-ggaaucgaaugaaaacucutt-3′ for braf; pooled duplex 1 sense, 5′-ggacuuuucuucagagauatt-3′; duplex 2 sense, 5′-ggacuggaguaauaucagatt-3′ and duplex 3 sense, 5′-ccaacacucucuaccgaaatt-3′ for craf. the dinucleotide “tt” was added to all sirnas to improve the stability after transfection. after 48 h, medium was changed to rpmi-1640 with 10% fbs. quantitative pcr and western blot were performed 72–96 h post-transfection. biological triplicates were used for each sirna treatment.",pmc4254013,1,100,40,1,140
hras,protein,,hras,uniprot,q04906,plasma membrane,go:0005886,akt1,protein,,akt1,uniprot,p11213,plasma membrane,go:0005886,positive,d,binds,,,epithelial-like,lung,human,['100'],nan,nan,ras signature distribution and prevalence in lung and breast tumors,pmc2911390,1,100,40,1,140
ksr,protein,,ksr,uniprot,q92739,plasma membrane,go:0005886,ras,protein,,ras,uniprot,q92738,plasma membrane,go:0005886,positive,d,binds,,,,,mammalian,['8'],nan,nan,ksr (kinase suppressor of ras) genes were initially identified in c. elegans and drosophila melanogaster as positive regulators of ras/mapk signaling [26-28].,pmc4020307,1,100,40,1,140
page4,protein,,page4,uniprot,q9h2a6,cytoplasm,go:0005734,p21,protein,,cdkn1a,uniprot,q96eu1,nucleus,go:0005734,positive,d,regulation,,pc3,adenocarcinoma,prostate,human,['79'],nan,nan,"we have previously shown that silencing page4 expression inhibits cell survival and enhances chemo-cytotoxicity in prostate cancer cells [16]. in such circumstance, page4 may protect cancer cells through upregulation of p21 in most stress status with exception of h2o2, in which p21 level was not altered in either page4-expressing cells or page4-knocking down cells [10]. to investigate how page4 is involved in oxidative stress protection in prostate cancer, we established inducible page4-overexpressing cell lines, in which both mrna and protein levels of page4 were significantly increased by treatment of dox (fig. 2 a, b). as shown in fig. 2 b, c, d, the expression of page4 were induced by h2o2 both in empty vector and page4 construct-transfected cells, even though the basic mrna level of page4 was much higher in page4 construct-transfected cells than empty vector-transfected cells. the fact that both endogenous and exogenous page4 gene can be induced by ros suggests that the regulation of page4 by ros may be related to a post-transcriptional way.",pmc6339303,1,100,40,1,140
map4k4,protein,,map4k4,uniprot,q96773,plasma membrane,go:0005886,pp2a,protein,,ppp2r1a,uniprot,p00167,plasma membrane,go:0005886,positive,d,modulates,,,b-cell,,vein,['142'],nan,nan,"map4k4 regulates erk activation through modulating pp2a activity. (a) the whole‐cell lysates of map4k4 shrna‐knockdown or ha‐overexpressing, shrna control or ha‐control, and their parental cell lines were used for ib with indicated antibodies. (b) pp2a activity of indicated cells was measured using pp2a immunoprecipitation phosphatase assay kit. * and ** denote a statistically significant difference, p < 0.05 and p < 0.01, respectively. (c) whole‐cell lysates of h23 shrna control cells (sh‐c), h23 map4k4‐knockdown cells (sh‐m 1) with and without pp2a inhibitor oa (5 nm) treatment for 24 h beforehand, a549 ha‐control cells (ha‐c) and a549 map4k4 ha‐overexpressing cells (ha‐m) with or without pp2a activator fty720 (2.5 μm) treatment for 24 h beforehand were used for ib with indicated antibodies.",pmc5467491,1,100,40,1,140
crebbp,protein,,crebbp,uniprot,q15373,nucleus,go:0005634,gr,protein,,gr,uniprot,p05578,cytoplasm,go:0005634,positive,d,binds,,,,,mouse,['35'],nan,nan,stable crebbp knockdown impairs expression of gr target genes but does not alter response to gc,pmc5395114,1,100,40,1,140
map4k4,protein,,map4k4,uniprot,q96km7,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,p00611,plasma membrane,go:0005886,positive,d,overexpression,,a549,epithelial-like,lung,human,['141'],nan,nan,"to further test that map4k4 bypasses mek to activate erk, we tested whether overexpression of map4k4 prevents mek inhibitor‐mediated inhibition of erk. the results showed that ectopic expression of map4k4 in a549 cells partially prevented mek inhibitor trametinib‐mediated inhibition of erk phosphorylation (fig. s4a), supporting that map4k4 activation could bypass the effect of mek inhibitor. consistent with this, we found that concurrent inhibition of map4k4 and mek with specific inhibitors exerted synergistic inhibitory effect on h23 cell proliferation (fig. s4b).",pmc5467491,1,100,40,1,140
nm23,protein,,nm23,uniprot,q92663,cytoskeleton,go:0005739,ras,protein,,ras,uniprot,q92663,cytoskeleton,go:0005739,negative,d,binds,,,epithelial-like,,human,['7'],nan,nan,the metastasis suppressor nm23 as a modulator of ras/erk signaling,pmc4020307,1,100,40,1,140
n-rasg12v,protein,,rasal1,uniprot,q96777,plasma membrane,go:0005886,stat3,protein,,stat3,uniprot,q96777,mitochondria,go:0005739,positive,d,phosphorylation,s727,,,,,['4'],nan,nan,n-rasg12v transformation requires the mek-erk pathway and s727 phosphorylation of mitochondrial stat3.,pmc3843736,1,100,40,1,140
cd200,protein,membrane-associated glycoprotein,cd200,uniprot,q92652,plasma membrane,go:0005886,erk,protein,mapk,mapk8,uniprot,p00722,cytoplasm,go:0005634,positive,d,phosphorylation,,,b-cell,,vein,['72'],nan,nan,"cd200, a type i membrane-associated glycoprotein and member of the immunoglobulin superfamily is highly expressed on melanoma cells and was found to be regulated by erk activation (40). cd200 mrna expression levels were found to be positively correlated with tumor progression. moreover, mek inhibition with u0126 and knockdown of mutant braf resulted in reduced expression of cd200 mrna in melanoma cell lines. of note, through interaction with the cd200 receptor, which is expressed on macrophages and dc, cd200 mediates an inhibitory signal (41). in mixed lymphocyte reactions with t cells, dcs, and melanoma cells, t cells produced larger amounts of il-2 when cd200 in melanoma cells was knocked down with shrna specifically targeting the cd200 ligand (42). these data suggest a link between mapk/erk activation in melanoma and the ability of dcs to activate t cells.",pmc3809567,1,100,40,1,140
bet,protein,,bet1,uniprot,q92578,nucleus,go:0005634,mek,protein,,mek1,uniprot,q92577,cytoplasm,go:0005634,positive,d,binds,,,,,,['145'],nan,nan,synergy for bet/mek combinations in ras pathway wild type cell lines,pmc5908790,1,100,40,1,140
belinostat,drug,hdac inhibitor,hpa000627,uniprot,qvqlqqsgaevkkpgasvkvsckasgytftdywgqgtlvtvss,cytoplasm,go:0005739,mapk,protein,,,uniprot,q92574,cytoplasm,go:0005739,positive,d,inhibition,,lung scc,epithelial-like,lung,human,['16'],nan,nan,"the current study highlights the therapeutic efficacy of belinostat in lung scc cells and characterizes the downstream molecular signaling in belinostat‐treated cells. we have previously identified activation of mapk/erk as a mechanism of resistance to cisplatin (kong et al., 2015). the increase in erk phosphorylation upon cisplatin treatment was shown to be regulated by son of sevenless (sos) upstream. the current study demonstrates the promising chemosensitizing characteristic of belinostat in lung scc through the suppression of mapk activity. we further studied the mechanistic actions of hdac inhibition by analyzing the global gene expression profiling, and identified the possible role of ubiquitin‐proteasome pathway in the regulation of sos/mapk signaling.",pmc5537703,1,100,40,1,140
nras,protein,,nras,uniprot,q92536,plasma membrane,go:0005886,kras,protein,,kras,uniprot,q92537,plasma membrane,go:0005886,negative,d,affects,codons 12 and 13,,,,human,['82'],nan,nan,all except three nras mutations and three quarters of the kras mutations affected the codons 12 and 13 (supplementary figure s6).,pmc5886052,1,100,40,1,140
braf,protein,,braf,uniprot,q92677,cytoplasm,go:0005629,erk,protein,,mapk3,uniprot,p04277,cytoplasm,go:0005629,negative,d,inhibits,,,,,human,['43'],nan,nan,brafv600e-mutated human thyroid carcinoma cells are insensitive to relief of erk dependent upstream negative feedback.,pmc5599027,1,10,38,1,48
mek,protein,,mapk8,uniprot,p00464,cytoplasm,go:0005886,ras,protein,,ras,uniprot,q00647,plasma membrane,go:0005886,positive,d,inhibition,,,,,human,['83'],nan,nan,"in conclusion, clonal mutations in nras, kras, ptpn11 and flt3 are associated with therapy resistance. given that clonal mutations at initial diagnosis were retained at relapse and that subclonal mutations often expanded at relapse, ras pathway mutations may serve as a biomarker to identify patients eligible for mek/erk targeted therapy. the synergistic effect between mek inhibition and prednisolone may be of additional advantage. while our results and supremacy of mek inhibitors require confirmation in independent cohorts, our data suggest screening (a) all cases that are eligible for treatment reduction based on mrd and (b) patients for whom treatment intensification is advised and who may benefit from adjuvant mek inhibitor treatment. methodically, accurate detection of any clonal ras pathway mutation should be ensured, but detection of subclonal mutations is not required.",pmc5886052,1,10,38,1,48
mek,protein,,mapk1,uniprot,q92675,cytoplasm,go:0005739,braf,protein,,braf,uniprot,q92676,cytoplasm,go:0005739,negative,d,inhibition,,,melanoma,,human,['29'],nan,nan,"because mek inhibition has better antitumor activity in melanoma harboring braf mutations than wild braf,12,13 clinical efficacy of hyd-sulfate selumetinib was evaluated in selected patients with braf mutant melanoma in another phase 2 study.38 in addition, all patients were stratified by activation of pi3k/akt pathway based on phosphorylated-akt (pakt) expression (high versus low) in the study, as pi3k/akt pathway is one of the critical regulators of selumetinib efficacy in braf mutant melanoma.22 the primary endpoint of the study was clinical response, and three objective clinical responses were observed in a total of 15 patients.38 all three responders had low pakt expression in the study. the estimated median pfs and os were 2.2 and 8 months in the high pakt cohort and 7.1 and 18 months in the low pakt cohort without statistical significance.38",pmc4179759,1,10,38,1,48
egfr,protein,,egfr,uniprot,p00614,plasma membrane,go:0005886,mek,protein,,mapk8,uniprot,q02852,cytoplasm,go:0005886,positive,d,phosphorylation,,,,,human,['92'],nan,nan,"8) the authors conclude that the inhibition of the egfr/mek/erk axis induces mostly a cell cycle arrest that, in absence of drug, can be reverted and cells proliferate again. i would be more cautious in this affirmation, given the data presented. it is not clear from the data presented whether there is a global cell cycle stop (no assessment of g1/s checkpoint activation nor cell cycle progression markers) and the data does not rule out the possibility of a small population of pre-resistant cells within the organoid, which are then able to repopulate in absence of treatment.",pmc5127645,1,10,38,1,48
ras,protein,,ras,uniprot,q92578,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,q92579,plasma membrane,go:0005886,positive,d,mutation,,,b-cell,,human,['192'],nan,nan,"intrachromosomal amplification of chromosome 21 (iamp21) identifies a high-risk subtype of acute lymphoblastic leukaemia (all), requiring intensive treatment to reduce their relapse risk. improved understanding of the genomic landscape of iamp21-all will ascertain whether these patients may benefit from targeted therapy. we performed whole-exome sequencing of eight iamp21-all samples. the mutation rate was dramatically disparate between cases (average 24.9, range 5–51) and a large number of novel variants were identified, including frequent mutation of the ras/mek/erk pathway. targeted sequencing of a larger cohort revealed that 60% (25/42) of diagnostic iamp21-all samples harboured 42 distinct ras pathway mutations. high sequencing coverage demonstrated heterogeneity in the form of multiple ras pathway mutations within the same sample and diverse variant allele frequencies (vafs) (2–52%), similar to other subtypes of all. constitutive ras pathway activation was observed in iamp21 samples that harboured mutations in the predominant clone (⩾35% vaf). viable iamp21 cells from primary xenografts showed reduced viability in response to the mek1/2 inhibitor, selumetinib, in vitro. as clonal (⩾35% vaf) mutations were detected in 26% (11/42) of iamp21-all, this evidence of response to ras pathway inhibitors may offer the possibility to introduce targeted therapy to improve therapeutic efficacy in these high-risk patients.",pmc5017527,1,10,38,1,48
raf,protein,,raf1,uniprot,q92043,plasma membrane,go:0005886,stat3,protein,,stat3,uniprot,p00309,nucleus,go:0005634,positive,d,phosphorylation,,j774a.1,macrophage,,mouse,['2'],nan,nan,the raf-mek-erk pathway is necessary for s727 phosphorylation of stat3 and transformation,pmc3843736,1,10,38,1,48
da-raf1,protein,,raf1,uniprot,q00644,plasma membrane,go:0005886,erk,protein,,mapk3,uniprot,p00841,plasma membrane,go:0005886,negative,d,suppresses,,,skeletal myocyte,muscle,mouse,['69'],nan,nan,intrinsic da-raf1 induces skeletal myocyte differentiation by suppressing the erk pathway,pmc2064279,1,10,38,1,48
braf,protein,,braf,uniprot,q96347,cytosol,go:0005736,mapk,protein,,,uniprot,mapk,cytosol,go:0005736,positive,d,activation,,,b-cell,,human,['71'],nan,nan,"constitutive upregulation of the mapk pathway by a brafv600 mutation occurs in about half of melanomas. this leads to increased oncogenic properties such as tumor cell invasion, metastatic potential, and resistance to apoptosis. blockade of the mapk pathway with highly specific kinase inhibitors induces unprecedented tumor response rates in patients with advanced brafv600 mutant melanoma. immune checkpoint blockade with monoclonal antibodies targeting cytotoxic t-lymphocyte antigen 4 and programed death-1/pd-l1 has also demonstrated striking anti-tumor activity in patients with advanced melanoma. tumor responses are likely limited by multiple additional layers of immune suppression in the tumor microenvironment. there is emerging preclinical and clinical evidence suggesting that mapk inhibition has a beneficial effect on the immunosuppressive tumor microenvironment, providing a strong rationale for combined immunotherapy and mapk pathway inhibition in melanoma. the t cell response has been the main focus in the studies reported to date. since dendritic cells (dcs) are important in the induction of tumor-specific t cell responses, the impact of mapk pathway activation in melanoma on dc function is critical for the melanoma directed immune response. brafv600e melanoma cells modulate dcs through the mapk pathway because its blockade in melanoma cells can reverse suppression of dc function. as both mek/braf inhibition and immune checkpoint blockade have recently taken center stage in the treatment of melanoma, a deeper understanding of how mapk pathway inhibition affects the tumor immune response is needed.",pmc3809567,1,10,38,1,48
map4k4,protein,,map4k4,uniprot,q92574,plasma membrane,go:0005886,erk1/2,protein,,mapk3,uniprot,p02154,plasma membrane,go:0005886,negative,d,inhibits,,,,,human,['139'],nan,nan,"whole‐cell lysates were prepared in m‐per buffer supplemented with protease inhibitor and phosphatase inhibitor (thermo fisher scientific, waltham, ma, usa), resolved by sds/page, and blotted with indicated antibodies. supersignal west pico chemiluminescent substrate and supersignal western blot enhancer (thermo fisher scientific) were used to enhance blotting signal when needed. the following antibodies were used in this study: anti‐map4k4, anti‐phospho‐erk1/2, anti‐phospho‐jnk, anti‐jnk, anti‐phospho‐p38, anti‐p38, anti‐akt, anti‐phospho‐akt, anti‐mek1/2, anti‐phospho‐mek1/2, anti‐ras and anti‐pp2a‐c (cell signaling technology, danvers, ma, usa); anti‐erk1/2, anti‐gapdh, anti‐β‐actin, anti‐pp2a‐b56β, and anti‐mkp3 (santa cruz biotechnology, dallas, tx, usa); anti‐6χ his (immunology consultants laboratory, inc., lake oswego, or, usa). erlotinib and trametinib were purchased from selleck chemicals (houston, tx, usa). the protein phosphatase 2 (pp2a) inhibitor okadaic acid (oa) was purchased from sigma aldrich. the pp2a activator fty720 was purchased from cayman chemical (ann arbor, mi, usa). map4k4 inhibitor pf‐06260933 was purchased from tocris bioscience (avonmouth, bristol, uk). egf was obtained from thermo fisher scientific.",pmc5467491,1,10,38,1,48
tgf-β1,protein,cytokine,tgfb1,uniprot,q92677,plasma membrane,go:0005886,fgf2,protein,cytokine,fgf2,uniprot,q92678,plasma membrane,go:0005886,positive,d,binds,,rle-6tn,epithelial-like,,rat,['110'],nan,nan,"rat aec2 cell line rle-6tn (rle) cells [48] were obtained from american type culture collection (atcc). rle cells were cultured in dulbecco’s-modified eagle’s medium/nutrient f-12 ham (dmem/f12) (sigma) containing 10% fbs and subcultured every 2 d. to induce emt, 1 104 cells/cm2 were cultured in dmem/f12 containing 1% fbs for 24 h and then stimulated with 0.5 ng/ml recombinant human tgf-β1 (r&d systems) dissolved in 4 mm hcl containing 0.1% bovine serum albumin for 48 h. to assess the effect of fgf2 on emt, cells were stimulated with 0.5 ng/ml tgf-β1 and 10–100 ng/ml recombinant human fgf2 (wako) with 100 μg/ml heparin. to analyze signaling pathways, cells were pretreated with 2–10 μm u0126 (promega) or 10 μm ly294002 (promega) for 30 min and then stimulated with 0.5 ng/ml tgf-β1 alone or in combination with 50 ng/ml fgf2.",pmc4440819,1,1,40,1,41
mek1,protein,,mapk8,uniprot,p00627,cytoplasm,go:0005634,selumetinib,drug,,,uniprot,azd6244,,go:0005634,negative,d,inhibition,,,,,human,['26'],nan,nan,"selumetinib (azd6244, arry-142886; astrazeneca, plc, london, united kingdom) is a highly selective, atp-uncompetitive allosteric inhibitor of both mek1 and mek2 and has the empirical formula of c17h15brclfn4o3 (figure 2). the half-maximal inhibitory concentration of selumetinib is 14.1 nmol/l against purified mek1 in vitro, whereas no inhibition of 40 other serine/threonine and tyrosine kinases was observed at concentrations up to 10 μmol/l.13",pmc4179759,1,1,40,1,41
ras,protein,,ras,uniprot,q92379,cytoplasm,go:0005634,siah,protein,,siah,uniprot,q92379,cytoplasm,go:0005634,positive,d,expression,,,b-cell,,vein,['185'],nan,nan,"siah expression reflects ras pathway activation, cell proliferation, and tumor growth (schmidt et al., 2007, ahmed et al., 2008, tang et al., 1997). as a therapy-responsive and tumor heterogeneity-independent ras pathway biomarker, siah is uniquely positioned to identify super-responders, partial-responders, and non-responders in the neoadjuvant setting to allow real-time monitoring, augmentation and quantification of therapy efficacy, to improve clinical outcome and patient survival (fig. 6, a schematic illustration). we found that siah is a robust, tumor-specific and therapy-responsive tumor biomarker that can be used to identify which patients are most likely to benefit from a given nst regimen as a first-line therapy, and which patients should receive additional augmented and combinational therapies in the case of ineffective nst (fig. 2, fig. 3, fig. 4, fig. 5). independent of therapy-induced tumor debulking, siah expression post-nst appears to have important prognostic value to detect the emergence of resistant tumor clones, differentiate among partial responders, forecast tumor relapse or remission, and predict survival in malignant breast cancer (fig. 6).",pmc5049993,1,1,40,1,41
ras,protein,,hras,uniprot,q92575,plasma membrane,go:0005886,nrasq61r,protein,,,uniprot,q61r,plasma membrane,go:0005886,positive,d,phosphorylation,,human,melanoma,,mouse,['175'],nan,nan,"ras oncogenes can initiate cancer in animal models; however, their role in sustaining tumor development and progression has not been fully addressed (reviewed in reference [244]). there is significant in vitro and in vivo evidence that supports oncogenic nras as a key target for melanoma: (i) suppression of oncogenic nrasq61r by sirna results in reduced migration and invasion of human melanoma cells [245]; (ii) extinction of nrasq61k expression in melanomas of an inducible mouse model resulted in rapid, durable, and complete tumor regression within a few days, supporting the idea that constitutively activated nras acts as a tumor-maintenance oncogene [246]; (iii) notably, mek inhibitors treatment (selumetinib plus gsk1120212) was unable to induce tumor regression in nrasq61k-mutant murine melanomas [246] as well as in human xenografts [247].",pmc6472057,1,1,40,1,41
braf,protein,,braf,uniprot,p00724,cytoplasm,go:0005886,kitlg,protein,,kit,uniprot,p00724,cytoplasm,go:0005886,positive,d,phosphorylation,,,b-cell,,human,['137'],nan,nan,"we next evaluated the effect of braf inhibitors (vemurafenib, a specific inhibitor of the braf v600e mutation, and dabrafenib, specific for braf v600e and v600k variants) in cells from 17 cll cases, nine containing mutations in genes of the ras-braf-mapk-erk pathway (kitlg, ptpn11, kras, braf, mapk1, map2k1 and map2k2) and eight u-ighv cll cases with no alterations in this pathway. vemurafenib, at a dose of 2.5 μm, was not able to inhibit basal erk phosphorylation or after anti-igm stimulation in mutated cases, while a slight effect was observed after treatment with 2.5 μm of dabrafenib. furthermore, upregulation of phosphorylated erk, was observed in the u-ighv cll cases with no mutations in the ras-braf-mapk-erk pathway after incubation with 2.5 μm of dabrafenib (p<0.05) (figure 4a).",pmc6395334,1,1,40,1,41
src,protein,,src,uniprot,q02305,plasma membrane,go:0005886,mapk pathway,signalingpathway,,,uniprot,,plasma membrane,go:0005886,positive,d,phosphorylation,,,,,human,['118'],nan,nan,"taken together, our data provides a critical piece of information in regards to the role of src in thyroid cancer, and the patient populations most likely to respond to the combined inhibition of src and the mapk pathway. in addition, the identification of rps6 phosphorylation as a biomarker of response to the combined inhibition of src and the mapk pathway provides an important tool for the identification of drug tolerant persisters, and the future determination of pathways that mediate resistance to this combination strategy. finally, we predict that the discoveries presented in this study will pave the way for improved responses, and enhanced overall survival for patients with advanced papillary and anaplastic thyroid cancer.",pmc5833015,1,1,40,1,41
mtorc1,proteincomplex,,rps6ka1,uniprot,q9h7c9,plasma membrane,go:0005886,protein synthesis,biologicalprocess,,,uniprot,,cytoplasm,go:0005632,negative,d,inhibits,,,,,,['12'],nan,nan,"when cell cycle is blocked, the high level mtorc1 favors the protein synthesis and cell hypertrophy, maintains energy homeostasis, senescence-associated secretory phenotype (sasp) and viability [23, 25, 41]. however, in control ras-transformed cells elevated activity of mtorc1 provides viability and supports high proliferation rate. therefore, we asked how mek/erk inhibition by pd0325901 affects the viability of cells induced to senescence with nabut and whether pd0325901 is able to induce ampk-dependent autophagy in the senescent cells.",pmc5723691,1,1,40,1,41
ras,protein,,hras,uniprot,q92079,plasma membrane,go:0005886,lc3,protein,,lc3,uniprot,q92079,cytoplasm,go:0005886,positive,d,colocalization,,,b-cell,,vein,['14'],nan,nan,"the most significant changes occur in the colocalization of the ras protein. while in untreated control, in pd0325901-treated and in senescent eras cells the ras protein is localized under plasma membrane (fig. 9b), no membrane-bound ras has been detected in senescent cells upon 72 h of pd0325901 treatment. immunofluorescence staining using antibodies against ras and lc3 indicates that ras colocalizes with lc3 in the cytoplasm of cells co-treated with nabut and pd0325901 for 24 h. thus, ras re-localizes from the membranes to the cytoplasmic structures in senescent cells upon pd0325901 treatment, where it most possibly fails to function as a regulator of signal transduction and autophagy. thus, in senescent cells pd0325901 does not only inhibit the mer/erk pathway, but also promotes the oncogenic ras re-localization, thereby disrupting its function as an autophagy regulator in senescent eras cells [7, 8].",pmc5723691,1,1,40,1,41
braf,protein,,braf,uniprot,p00737,plasma membrane,go:0005886,ret,protein,,ret,uniprot,q00944,plasma membrane,go:0005886,positive,d,activating-point mutation,,,none,none,human,['38'],nan,nan,"rearrangements of the gene encoding the receptor tyrosine kinase ret and activating-point mutations of ras or braf are found in 70% of all cases of ptc and are mutually exclusive. mutation of braf, especially a valine to glutamic acid substitution at codon 600 (v600e) termed the brafv600e mutation, is the most frequent genetic alteration, identified in 60% of cases (range: 27%-87%) [1, 2]. ptcs with different mutations are recognized to have distinct histopathologic appearance and biologic properties. most studies in ptcs suggest that braf activating mutation is closely associated with extrathyroidal extension, lymph node metastasis, advanced tumor stages, disease recurrence, and even patient mortality [2]. the molecular mechanisms underlying the association of braf mutation with worse prognosis compared to ptc with no or other genetic alterations has so far only been partially elucidated. there is evidence that the transcriptional output of the mapk pathway is greatest in brafv600e mutant tumors, because this oncoprotein signals as a monomer and is therefore unresponsive to feedback inhibition on raf dimers [3].",pmc5599027,1,1,40,1,41
mapk,protein,,,uniprot,,,,extracellular signal-related kinases (erks),protein,,,uniprot,,,,positive,d,phosphorylation,,,,,mammalian,['173'],nan,nan,"the mapk signaling pathways are evolutionarily conserved signal transduction pathways, which regulate a variety of fundamental cellular processes, including cell proliferation, differentiation, senescence, survival, transformation, and migration (reviewed in references [43,44,45]). these signaling pathways are characterized by the distinctive feature of linear/vectorial cascades of phosphorylation events, which spread from the cell membrane to the nucleus. the mapk pathway activates with the interaction of a broad spectrum of extracellular signals—including mitogens, growth factors, and cytokines—with specific plasma membrane receptors. this interaction triggers a hierarchical cascade of phosphorylation events that ultimately terminates with the activation of specific map kinases (mapks)—their catalytic activity determines the specific signaling response of a given pathway, i.e., the activation/repression of a specific set of genes in the nucleus together with the activation/repression of specific cellular functions in the cytoplasm. in the mammalian genome, there are 14 mapks, which are organized into three groups, corresponding to as many distinct phosphorylation cascades and signaling pathways: (i) the extracellular signal-related kinases (erks), (ii) the c-jun n-terminal kinases (jnks), and (iii) the stress-activated protein kinases (p38/sapks) (reviewed in reference [46]). each group of mapks is activated, upon phosphorylation, by group-specific mapk kinases (mapkks or map2ks), which, in turn, are phosphorylated by group-specific mapkk kinases (mapkkks or map3ks), which are typically activated by group-specific small gtpases, upon binding to plasmalemma receptors. while the mapk/jnk and the mapk/p38 signaling pathways are mostly related to the regulation of the immune response and are activated by cellular stress conditions (including the oxidative, genotoxic, and osmotic stress), the map/erk signaling pathway plays a crucial role in cancer development by promoting cell proliferation and migration; this latter pathway is mainly activated by growth factors (reviewed in references [47,48]).",pmc6472057,1,1,40,1,41
k-rasv12,protein,,kras,uniprot,q92579,plasma membrane,go:0005886,mts-stat3,protein,,,uniprot,,mitochondria,go:0005739,negative,d,binds,,mef,immune,,mouse,['3'],nan,nan,"k-rasv12 transformed wild-type (kras), stat3-/- mefs (kras:stat3-/-) or kras:stat3-/- mefs stably transduced with mitochondrially restricted stat3 (kras:stat3-/-+mts-stat3) or mitochondrially restricted phospho-s727 mimetic mutant stat3 (kras: stat3-/- +mts-stat3 s/d) cells were plated in media supplemented with 0.3% agar and the indicated dose of pd0325901 or vehicle (unt) and colonies counted 14 d later. each point represents the mean of biological triplicates, error bars are ±1 standard deviation from the mean. we used student’s t-test to determine significant differences. * denotes p<0.05, *** denotes p<0.001.",pmc3843736,1,1,40,1,41
mapk,protein,,,uniprot,,cytoplasm,go:0005637,fibroblasts,cell,,,uniprot,,cytoplasm,go:0005637,positive,d,phosphorylation,,,mesodermal,,human,['148'],nan,nan,"kinase (mapk), the main members of mapk pathway, are expressed predominately by",pmc6113736,1,1,40,1,41
kras,protein,,kras,uniprot,q05272,plasma membrane,go:0005886,ccle,cellline,,,,,,,positive,d,expression,,,,,,['62'],nan,nan,ccle cell lines with kras mutations also show an associated increase in kras expression,pmc5467702,1,1,40,1,41
kras,protein,,kras,uniprot,q96354,cytoplasm,go:0005739,egfr-mek-erk pathway,signalingpathway,,,uniprot,egfr-mek-erk,cytoplasm,go:0005739,positive,d,activates,,breast cancer cells,epithelial,breast,human,['94'],nan,nan,we strengthened our evidence that kras mutant tumor cells are blocked in cell cycle progression upon inhibition of the egfr-mek-erk pathway. these data are now included as a new figure 8.,pmc5127645,1,1,40,1,41
peroxisome proliferator-activated receptor γ (pparγ),protein,,pparg,uniprot,q92574,nucleus,go:0005739,retinoid x receptor (rxr),protein,,rxra,uniprot,q04173,nucleus,go:0005739,positive,i,binds,pparγ-responsive element (ppre),,,,human,['186'],nan,nan,"peroxisome proliferator-activated receptor γ (pparγ) is one of ligand-activated transcription factors within the nuclear steroid hormone receptor superfamily and forms a sub-family along with the other two subtypes, pparα and pparβ/δ [6]. rosiglitazone (rgz) is known to be a ligand for pparγ [7]. transcriptional regulation by ppars requires heterodimerization with the retinoid x receptor (rxr), and then the heterodimeric complex binds to pparγ-responsive element (ppre), consequently triggering the expression of numerous target genes [8, 9]. although substantial studies on pparγ have focused on the mechanisms by which pparγ regulates glucose and lipid metabolism, reports over the past several years have suggested that pparγ might play additional roles in inflammatory response and cancer. a recent study showed that thiazolidinedione-activated pparγ had an ability to repress the proliferation of estrogen-dependent breast cancer cells and pparγ might act as a therapeutic target in human breast cancer [10]. the role of pparγ in the progression of esophageal cancer remains controversial: activation of pparγ inhibits cell growth and induces apoptosis in vitro; however, pparγ agonists promote tumor growth in xenografted mice. this discrepancy may be related with in vivo effects of “tumor interactions”, pparγ activation magnitude, and pparγ-independent effects of agonists [11]. therefore, the role of pparγ on esophageal cancer cells and the mechanisms in the response to pparγ agonists in esophageal cancer cells remain to be further elucidated.",pmc5190119,1,1,40,1,41
nf-κb p65,protein,transcription factor,rela,uniprot,p00717,nucleus,go:0005739,bcl-xl,protein,member of bcl-2 family,bcl2l1,uniprot,q07817,mitochondria,go:0005739,positive,d,expression,,,b-cell,,human,['81'],nan,nan,"the prognosis of children with b-cell precursor acute lymphoblastic leukemia (bcp-all) has improved considerably over the past decades, and nowadays about 80% of the patients are cured.1 however, especially medium- and high-risk cases still show dissatisfying rates of relapse despite intense chemotherapy.2, 3, 4 relapsed all is treated with the same drugs as the initial leukemia, but cells of relapsed cases are more resistant.5 new, targeted approaches are therefore warranted.",pmc5886052,1,1,40,1,41
ras proteins,protein,,ras,uniprot,q92077,plasma membrane,go:0005886,gaps,protein,,gap,uniprot,q96117,plasma membrane,go:0005886,negative,d,inhibition,,,none,none,human,['58'],nan,nan,"ras proteins act as molecular switches: the guanosine diphosphate (gdp)–bound form is inactive and guanosine triphosphate (gtp)–bound form is the active state. guanosine triphosphatase (gtpase)–activating enzymes (gaps) stimulate low-level intrinsic gtpase activity and convert ras proteins to their inactive gdp-bound forms, whereas corresponding exchange enzymes (guanine nucleotide exchange factors [gefs]) catalyze the replacement of gdp with gtp to activate the switch.5 in cancer, mutations (primarily in codons 12, 13, and 61) render ras proteins resistant to gap-assisted gtp hydrolysis resulting in a constitutively active ras molecule.6,7 less frequently, mutations occur (eg, at alanine 146) that lower the affinity of ras proteins for gdp, allowing exchange of gdp for gtp without upstream signaling through gefs.7 importantly, these activating mutations in kras affect both the kras4a and kras4b isoforms.",pmc5467702,1,1,40,1,41
src,protein,,src,uniprot,q01507,plasma membrane,go:0005886,mapk pathway,signalingpathway,,,uniprot,,,,positive,d,inhibition,,,,,human,['117'],nan,nan,"src-driven oncogenesis has been well documented in a number of cancers, however unlike typical oncogenic drivers, src is rarely mutated27,28. we previously demonstrated that chronic src inhibition promotes an increased reliance of thyroid cancers on the mapk pathway, and that the upfront combined inhibition of src and the mapk pathway can prevent/delay resistance from occurring10. our study, along with others highlighting synergy between the combined inhibition of src and the mapk pathway, support a role for src in mediating resistance to inhibitors of the mapk pathway, in thyroid cancer10–12. therefore, we set out to determine which patients would benefit from the combined inhibition of src and the mapk pathway.",pmc5833015,1,1,40,1,41
stat3,protein,transcription factor,stat3,uniprot,q92465,nucleus,go:0005739,s727k mutant of stat3,protein,,,uniprot,,,go:0005739,positive,d,phosphorylation,s727,ras transformed cells,b-cell,,human,['1'],nan,nan,the raf-mek-erk pathway is required for s727 phosphorylation of stat3 in ras transformed cells,pmc3843736,1,1,40,1,41
src,protein,non-receptor tyrosine kinase,src,uniprot,q92074,plasma membrane,go:0005886,mapk pathway,signalingpathway,,,uniprot,,plasma membrane,go:0005886,positive,d,phosphorylation,rps6,,,,human,['113'],nan,nan,"advanced stages of papillary and anaplastic thyroid cancer continue to be plagued by a dismal prognosis, which is a result of limited effective therapies for these cancers. due to the high proportion of thyroid cancers harboring mutations in the mapk pathway, the mapk pathway has become a focal point for therapeutic intervention in thyroid cancer. unfortunately, unlike melanoma, a similar responsiveness to mapk pathway inhibition has yet to be observed in thyroid cancer patients. to address this issue, we have focused on targeting the non-receptor tyrosine kinase, src, and we and others have demonstrated that targeting src results in inhibition of growth, invasion, and migration both in vitro and in vivo, which can be enhanced through the combined inhibition of src and the mapk pathway. therefore, we examined the efficacy of the combination therapy across a panel of thyroid cancer cell lines representing common oncogenic drivers (braf, ras, and pik3ca). interestingly, combined inhibition of src and the mapk pathway overcomes intrinsic dasatinib resistance in cell lines where both the mapk and pi3k pathways are inhibited, which we show is likely due to the regulation of the pi3k pathway by src in these responsive cells. interestingly, we have mapped downstream phosphorylation of rps6 as a key biomarker of response, and cells that maintain rps6 phosphorylation likely represent drug tolerant persisters. altogether, the combined inhibition of src and the mapk pathway holds great promise for improving the overall survival of advanced thyroid cancer patients with braf and ras mutations, and activation of the pi3k pathway and rps6 phosphorylation represent important biomarkers of response for patients treated with this therapy.",pmc5833015,1,1,40,1,41
src,protein,non-receptor tyrosine kinase,src,uniprot,q92579,plasma membrane,go:0005886,thyroid cancer cells,cell,,,,,,,positive,d,phosphorylation,,dasatinib-resistant,,,human,['114'],nan,nan,"our work and the work of others have highlighted a role for the non-receptor tyrosine kinases src family kinases (src) in mediating thyroid tumorigenesis7–9, and importantly we have demonstrated that prolonged inhibition of src reprograms cells to become more reliant on the mapk pathway10. in support of this data, multiple laboratories have demonstrated that the combined inhibition of src and the mapk pathway results in synergistic inhibition of growth and increased apoptosis of thyroid cancer cells both in vitro and in vivo10–12. altogether, these data support the hypothesis that src may mediate resistance to mapk pathway targeted therapies, and that co-targeting src and the mapk pathway will result in enhanced clinical responsiveness. having previously observed efficacy with the combined inhibition of src and mek1/2, in cell lines sensitive to the src inhibitor dasatinib10, we hypothesized that dasatinib-intrinsically resistant cell lines would also respond to combined src and mek1/2 inhibition.",pmc5833015,1,1,40,1,41
stat3,protein,,stat3,uniprot,q05535,mitochondria,go:0005739,jak2,protein,,jak2,uniprot,q92377,plasma membrane,go:0005886,positive,d,phosphorylation,s727,hek 293t,epithelial-like,kidney,human,['5'],nan,nan,"stat3 is over-expressed and/or post-translationally modified in the majority of human cancers. the current dogma for the contribution of stat3 to cancer biology is as a potent transcription factor driving expression of genes controlling numerous hallmark features of tumor cells [2]. this paradigm is clearly implicated for oncogenes that target y705 phosphorylation of stat3 (e.g., jak2, egfr, npm-alk), but it is less clear why stat3 would be important for non-tyrosine kinase oncogenes that do not lead to stat3 tyrosine phosphorylation (e.g., h-, n-, k-ras and c-myc). nonetheless, we recently showed that the ras family of oncogenes requires stat3 expression to transform cells. importantly, this requirement for stat3 was found to be due to a mitochondrial pool of stat3 that augments the activity of the electron transport chain, lactate dehydrogenase activity, and atp abundance [12]. the mitochondrial activity of stat3 and ras-mediated transformation is dependent on the phosphorylation of stat3 on s727. many kinases have been shown to phosphorylate stat3 on s727 in a stimulus dependent manner (e.g., erk, jnk, p38, mtor, sec1, pkcδ, and rac- and vav-dependent kinases [8,29]). however, it has not been documented which serine kinase(s) activated by the ras oncogenes are responsible for serine phosphorylation of stat3. in this study, we provide experimental evidence that the erk pathway is responsible and critical for this modification.",pmc3843736,1,1,40,1,41
braf,protein,,braf,uniprot,q96334,cytoplasm,go:0005739,melanocyte,cell,,,,,cytoplasm,go:0005739,positive,d,activates,,,melanocyte,,human,['74'],nan,nan,"in humans, brafv600e mutations are found in benign nevi (pollock et al., 2003), clonal populations of senescent melanocytes (gray-schopfer et al., 2006). brafv600e can stimulate senescence in human melanocytes in vitro (michaloglou et al., 2005). hence, nevi might represent the result of oncogene-induced senescence. nevertheless, formation of a nevus requires an initial pulse of melanocyte proliferation, and mapk signaling appears to be essential for this step. this has been very elegantly shown in zebrafish that develop invasive melanoma induced by mutant ras, which is however completely abolished when ras is rendered incapable of activating mapk signaling (michailidou et al., 2009). importantly, these fish do not even develop nevi, clearly demonstrating that no melanocyte proliferation had occurred in the absence of constitutive mapk signaling, and tumor initiation was completely blocked (michailidou et al., 2009).",pmc4846800,1,1,40,1,41
dusp1,protein,nuclear,dusp1,uniprot,p00326,nucleus,go:0005739,dusp2,protein,nuclear,dusp2,uniprot,p00327,nucleus,go:0005739,positive,d,phosphorylation,,,,,human,['42'],nan,nan,"pronounced compensatory increase in transcription of one dusp when the other is knockdowned has been observed for dusp1 and dusp2 [45]. in our work dusp5 inactivation is combined with a clear compensation by dusp6 at the mrna and protein levels which may explain the absence of consequence on proliferation and p-erk levels. as previously demonstrated, a slight increase in the nuclear levels of p-erk occurs upon inactivation of dusp5, without any changes in p-erk levels in the total extract [33]. this increase in the nuclear levels of p-erk may explain the compensatory increase in dusp6 mrna and protein. the absence of consequences of a double inhibition of dusp5 and dusp6 on p-erk levels and cell viability could suggest subtle changes in the levels of p-erk occurring at the nuclear level only or a compensatory increase in other dusps or other phosphatases. other members of the dusp family that dephosphorylate erk are induced by mapk signaling (the nuclear dusp1, dusp2 and dusp4; the cytosolic dusp7 and dusp9) [8] and are, thus, good candidate genes to study in order to understand the compensatory increase in this context. subtle changes in the spatiotemporal regulation and activity of erk induced by dusp5 and dusp6 inactivation may also explain the observed impact on invasion and migration in bcpap and 8505 cells. however, we cannot formally exclude the possibility that dusp5 and dusp6 regulate tumor cell migration and invasion independently of erk. in conclusion, our data confirmed that dusp5 and dusp6 mrna levels are markers of activation of the mapk signaling pathway in ptcs. higher output of the mapk pathway in brafv600e mutated thyroid carcinomas provides an explanation for their poorer prognosis compared to other ptcs. dusp5 and dusp6 have no tumor suppressor properties in two brafv600e thyroid carcinoma models, but instead they seem to have a protumorigenic role on thyroid carcinogenesis. the lack of effect in proliferation after specific inhibition of dusp5 or dusp6 or both dusps suggests redundancy and functional compensation in the large family of dusp. future work should focus on transcriptomic analysis of dusps expression modification, more specifically compensatory changes when one or several dusps are inactivated in human thyroid cancer cell lines.",pmc5599027,1,1,40,1,41
stat3,protein,,stat3,uniprot,q92679,cytoplasm,go:0005634,cytokine,protein,,,uniprot,,plasma membrane,go:0005886,positive,d,phosphorylation,s727,,b-cell,,human,['0'],nan,nan,"phosphorylation of stat3 on serine 727 (s727) also occurs in response to cytokine stimulation and enhances its transcriptional efficacy [8]. s727 phosphorylation of stat3 has also been found to be constitutive in hematological malignancies (e.g., b-cell derived tumors and pediatric acute myeloid leukemia) [9,10]; however the only oncogenes that we are aware of that lead to s727 but not y705 phosphorylation belong to the ras family. the ras oncogenes are the most common activating mutation in human cancer [11]. mutation at codons 12, 13 or 61 locks ras in a gtp bound active state, which initiates diverse signaling cascades including raf-mek-erk, pi3k and ral pathways that drive proliferation, survival and angiogenesis [11]. the ras family of oncogenes (h-, n- and k-) do not directly stimulate stat3 y705 phosphorylation, yet stat3 is still essential for transformation by these oncogenes [12]. this requirement for stat3 in ras-transformation was shown to require the s727 phosphorylated form of stat3.",pmc3843736,1,1,40,1,41
e2f,protein,,e2f1,uniprot,q04676,nucleus,go:0005739,cancer cells,other,,,fplx,cancer cells,cytoplasm,go:0005886,positive,d,expression,,,,,human,['95'],nan,nan,"first, we performed cell cycle analysis by flow cytometry. most notably, after 72hrs of drug treatment we observed that most cancer cells accumulate in g1 at the expense of tumor cells in s-phase. indeed, this is in agreement with our live-cell imaging data of the drug response, where virtual no mitotic events were detected towards the end of the treatment.",pmc5127645,1,1,40,1,41
egfr,protein,,egfr,uniprot,p00728,cytoplasm,go:0005634,rab35,protein,,rab35,uniprot,q92338,cytoplasm,go:0005634,positive,d,upregulation,,dld-1,epithelial-like,colon,human,['144'],nan,nan,"to further strengthen the evidence for ncoa3, foxo3, and tcf7l2 as mediators of the ras pathway, we performed lc-ms-based global proteomics and observed several significant changes in ras pathway proteins. these included fgf2, lgals1, plcg2, cdkn1a, erbb2, fyn, epha2, rab8a, mapkapk2, rb1, ikbkb, rab35, rab3a, and egfr, with cdkn1a upregulated in all four knockdown lines. in contrast, fewer ras-related proteins were modulated in the three stable knockdown lines in dld-1 kraswt/- genetic background. this is in agreement with ncoa3, foxo3, and tcf7l2 having roles in the activated ras pathway.",pmc5755028,1,1,40,1,41
p38 mapk,protein,,mapk3,uniprot,q04447,cytosol,go:0005739,empty plasmid,other,,,uniprot,,,go:0005739,negative,d,binds,,hek 293t,epithelial-like,,human,['67'],nan,nan,"cells were seeded into 6-well plates at a density of 1 × 106 cells/2.5 ml per well. after 24 h (allowing cells to attach), the culture medium was replaced with new culture medium containing 2.5 µg of plasmid dna (empty plasmid or plasmid containing p38 mapk) and lipofectamine 3000 (invitrogen, paisley, uk) as a transfection reagent according to the manufacturer’s instructions. after 48 h, the culture medium was replaced with a serum-free medium containing 2% bsa with or without sa. after 18 h of the treatment, cells were harvested and lysates were prepared for western blot analysis as described previously [8]. the efficiency of transfection was tested by analyzing the level of p38 mapk using western blot.",pmc4783893,1,1,40,1,41
egfr,protein,,egfr,uniprot,q05207,plasma membrane,go:0005886,fgfr3,protein,,fgfr3,uniprot,q07817,cytoplasm,go:0005634,positive,d,binds,,,b-cell,,human,['46'],nan,nan,"to avoid the heterogeneity of tumor sample from patients, here we applied a dataset (gse54326) to determine the erk pathway changes in epirubicin resistant tnbc cell line mda-mb-231. tumor cells were treated continuously within 25nm epirubicin to induce chemoresisrance. epirubicin resistant cells were morphologically different from native cells, and had alterations in several signaling pathways, the whole transcriptome was quantified with illumina human ht-12 v4.0 expression beadchip. similarly, it was also found that drug and other molecules metabolism pathways were enriched in epirubicin resistant tumor cells. abc transporters related genes expression was also enhanced in epirubicin resistant cells (figure 3). additionally, we found more erk signaling pathway component genes were enriched in epirubicin resistant cells, like mapk8ip3, mapk13 and map3k14, etc. (table 3). other upstream genes of erk signaling pathway such as egfr, fgfr3 were also enriched in resistant tumor cells (figure 4).",pmc5746140,1,1,40,1,41
tgf-β,protein,,tgfb1,uniprot,p00165,cytoplasm,go:0005886,type i protein ser/thr kinase receptors (tβri),protein,,,uniprot,p00166,cytoplasm,go:0005886,positive,d,binding,,,,,human,['107'],nan,nan,"tgf-βis generally recognized as a central mediator of the fibrotic response in physiological tissue repair and in many fibrotic diseases by inducing emt, activating fibroblasts, and promoting synthesis of the ecm components [9–13]. tgf-β signaling is induced through type i and type ii protein ser/thr kinase receptors (tβri and tβrii) [14]. tgf-β binding induces activating phosphorylation of dimeric tβris by dimeric tβriis. subsequently, the activated tβris recruit and phosphorylate receptor-regulated smad (r-smad), smad2/3. phosphorylated smad2/3 dissociates from the receptors and binds to co-smad, smad4. the activated smad2/3–smad4 heterotrimeric complex translocates into the nucleus and regulates the transcription of specific target genes together with transcriptional coactivators or corepressors.",pmc4440819,1,1,40,1,41
erk1,protein,,mapk3,uniprot,p00376,plasma membrane,go:0005886,thymocyte,cell,,,uniprot,tc000005,thymus,go:0005886,negative,d,phosphorylation,,,t-cell,thymus,mouse,['112'],nan,nan,"in haematopoietic system, in vivo analysis of erk1−/− mice has revealed an essential function of erk1 through thymocyte maturation 11. in addition, based on ex vivo studies, erk pathway plays a critical role in regulating differentiation of megakaryocyte 12, erythrocyte 13, 14, macrophage 15, as well as granulocyte and monocyte 16, 17. indeed, it seems that activation of erk pathway may somehow act as a stimulus for hscs to exit from the self‐renewal programme and enter into differentiation phase 18. furthermore, there is more evidence that erk1/2 signalling pathway may also be involved in regulation of other cellular processes of haematopoietic system 19.",pmc5824365,1,1,40,1,41
erk,protein,,erk1,uniprot,p00439,cytosol,go:0005886,h-ras,protein,,hras,uniprot,q07817,plasma membrane,go:0005886,positive,d,phosphorylation,s727,,b-cell,,vein,['6'],nan,nan,"the requirement of the erk pathway for h-ras transformation was also observed for k- and n-ras transformation, as indicated by the sensitivity of anchorage independent cell growth to pd0325901. inhibition of the mek-erk pathway blocked colony formation driven by all three activated ras isoforms (figures 2d, 3 and 4). to directly test the contribution of s727 phosphorylated mitochondrial stat3, we generated cells that exclusively expressed a mitochondrially restricted stat3 harboring a serine to aspartic acid mutation to mimic phosphorylation at s727. these cells were sensitive to h-, k-, and n-ras-mediated transformation. moreover, they were significantly less sensitive to mek inhibition when compared to cells expressing wild type stat3, when tested for anchorage independent cell growth. however, in the absence of mek inhibition, mts-stat3-s/d and total stat3-s/d expressing cells were equivalently responsive to ras transformation as cells expressing wild type stat3. these data suggest that activated ras is sufficient to maximally phosphorylate mitochondrial stat3, at least to an extent that saturates any function required for transformation. it is interesting to note that the mts-stat3-s/d mutant did not lead to an increase in the colony formation of ras transformed cells in the absence of pd0325901. it was also not transforming on its own. we hypothesize that phospho-s727 stat3 contributes to transformation by synergizing with additional mek-dependent targets required for transformation, probably by supporting a metabolic shift necessary for the transformed state.",pmc3843736,1,1,40,1,41
erk,protein,,mapk3,uniprot,p02179,cytoplasm,go:0005637,t-cells,cell,,tcr,,t-cells,cytoplasm,go:0005637,negative,d,inhibited,,,b-cell,,vein,['159'],nan,nan,"0.01). additionally, the effect of administration of tgn-020 on erk",pmc6113736,1,1,40,1,41
erk,protein,,,uniprot,,plasma membrane,go:0005886,ptprs,protein,,ptprs,uniprot,q05537,plasma membrane,go:0005886,negative,d,phosphorylation,erk,hct116,epithelial-like,kidney,human,['50'],nan,nan,"ptprs affects the localization of erk. (a) immunofluorescent staining shows erk nuclear localization in hct116 ptprs ko cells (upper left) and general whole cell staining in hct116 control cells (lower left). a comparison of the control cells to the ko shows that the ptprs ko cells have nuclei that are enriched with total erk (arrow in top left compared to arrow in bottom left). the erk phosphorylation in its location is confirmed with a mek inhibitor (pd98509, middle panels). the inhibition of mek prevent erk phosphorylation resulting in erk not being translocated to the nucleus (middle images have nuclei with very low-stained signals for erk). staining for phospho-erk (right panels) shows a very dynamic difference with the ptprs ko cells showing a bright signal and the control cells having very weak signal. supplementary fig. 4 shows the linear profile of fluorescence intensity for both dapi and erk/phospho-erk. these measurements confirm the increased signal seen in the nuclei of ptprs ko cells. (b) western blot for the cells in fig. 8a. the left two lanes are untreated hct116 cells and right two are treated with 5 μm of mek inhibitor pd98509 for 24 hours. the upper blot confirms the ptprs knockout in the ko cells. the lower blots for phospho-erk and total erk confirm the increased phospho-erk for the ptprs ko in the left two lanes. the right most lanes confirm that the meki prevented the phosphorylation of erk. (c) multichannel blot of cells transfected with ptprs with a c-terminal flag tag. this blot uses both a ptprs (rabbit green) and flag (mouse red) antibody. here the cleavage of ptprs is illustrated. full length ptprs is 217 kda (yellow), the n-terminal subunit containing extracellular and transmembrane domains are 140 kda (green) the c-terminal subunit containing phosphatase d1 and d2 domains are 78 kda (red). this cleavage was a consistent result, and seen in all cell lines used. (d) assessment of ptprs transfection on erk localization. hct116 and km12l4a ptprs ko cells were transfected with a rfp c-terminal tagged ptprs. here we examined the localization of ptprs (red) and total erk (green) as well as their co-localization (orange). the ptprs transfected cells (red) show a critically reduced level of erk in their nuclei (white arrows) when compared to the cells not over expressing ptprs (red arrows), which have bright green nuclei (erk). (e) western blotting corresponding to the cells used in 8d and 8f. the left three lanes show the ptprs ko compared to the control cells and ptprs ko cells transfected with ptprs. the third lane shows that ptprs transfected back into ptprs ko cells reduces the increased phospho-erk back to levels equivalent to the control cell line. the right three lanes show the isp inhibited the transfected ptprs activity allowing for increased phospho-erk. (f) the nuclear reduction of erk as a result of ptprs transfection is reversed when ptprs is inhibited by the isp. hct116 and km12l4a ptprs ko cells were transfected with the rfp tagged ptprs and then treated with the ptprs inhibitor isp. the reduction in nuclear erk (8d) is completely reversed (8f) when ptprs is inhibited. both the cells overexpressing ptprs (white arrows) and non-transfected cells (red arrows) show bright erk signal in their nuclei. supplementary fig. 5 shows the dapi stains for these images. (g) duo-link in situ staining for ptprs and erk co-localization. hct116 ptprs ko cells were transfected with a c-terminal flag tagged ptprs or control empty vector. the cells were then labeled with a flag mouse ab and an erk rabbit ab. the red dots indicate a successful duolink reaction, which requires both antibodies to be in close proximity. the ptprs transfected cells show an ample amount of red signal (left), and the empty vector cells do not show a significant amount of signal (right). these data suggest a direct association between ptprs and erk.",pmc6006154,1,1,40,1,41
p38 mapk,protein,,mapk14,uniprot,p00844,cytosol,go:0005634,mapkapk-2,protein,,mapkapk2,uniprot,q05779,cytosol,go:0005634,negative,d,silencing,,nes2y,fibroblast,,human,['66'],nan,nan,"in order to test the involvement of p38 mapk in apoptosis signaling induced by sa in nes2y cells, we assessed the effect of p38 mapk silencing by specific sirna on cell growth and viability after sa treatment. we also tested the effect of p38 mapk silencing on phosphorylation of mapkapk-2 (pathway member downstream of p38 mapk) and phosphorylation of erk pathway members (c-raf, mek1/2 and erk1/2) after sa application. to assess the efficiency of silencing, we measured the level of total p38 mapk and phospho-p38 mapk, respectively.",pmc4783893,1,1,40,1,41
cd4-,protein,,,uniprot,p01730,plasma membrane,go:0005886,tcr,other,,,fplx,tcr,plasma membrane,go:0005886,positive,d,phosphorylation,,,b-cell,,vein,"['21', '47', '84', '85', '91', '93', '126', '150', '155', '169', '190']","nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan","nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan","we sought to verify the changes in kinase phosphorylation by western blotting in independent cell lysates of belinostat‐sensitive (calu‐1, h520, h2170) and belinostat‐resistant cell lines (h226, h596, chago‐k‐1). scc cells were treated with increasing doses of belinostat that fall within the clinically achievable plasma concentration (yeo et al., 2012). of note, belinostat treatment abrogated the phosphorylation of erk1/2 and p38 in all scc cells, except for the highly resistant h226 cells (fig. 2c). consistently, upstream kinases of erk1/2, mek1/2, and b‐raf were inhibited by increasing doses of belinostat. as activation of the map kinase pathway limits the induction of apoptosis, we looked to see whether apoptosis was induced in belinostat‐treated cells. as expected, treatment with belinostat increased parp cleavage, a marker of apoptosis (fig. 2c, top). furthermore, belinostat dose‐dependent treatment significantly increased annexin‐v‐positive populations in belinostat‐sensitive cells (calu‐1, h520, and h2170), but not in belinostat‐resistant cells (chago‐k‐1, h596, and h226) (fig. 2d).,statistical analysis was done using student's t-test, variance analysis and/or non-parametric tests. for all the tests, p<0.05 was considered as statistical significance. all statistics were calculated by spss 13.0 or r software.,drug responses of patient-derived crc organoids with and without mutant kras.,first, we noticed a much lower sensitivity of p18t-krasg12d for pan-her inhibitors afatinib, lapatinib and dacomitinib in contrast to the parental p18t (much lower ic50, figure 3—figure supplement 1). second, within p18t hardly any additive sensitivity could be observed when egfri was complemented with mek or erk inhibition (figure 4—figure supplement 1). in contrast, dual-targeting strategies strongly enhanced efficacies in p18t-krasg12d regardless which specific inhibitor combination was used (figure 4—figure supplement 1). nevertheless, all tested combinations that included egfr inhibition revealed stronger negative effect on cellular viability in p18t than in p18t with mutant kras (positive δic50’s, figure 4—figure supplement 1). in contrast, most mono- and combination therapies against mek and/or erk that excluded egfri showed on average similar efficacies in p18t-krasg12d as in p18t (figure 4—figure supplement 1).,the results presented are representative of three independent experiments run in triplicate, unless otherwise indicated. student’s t test and two-way anova were carried out using graphpad prism to calculate significance. differences were considered significant at p<0.05. results are expressed as mean ± standard error (s.d.).,[editors' note: further revisions were requested prior to acceptance, as described below.],geneplots are shown for the 50 most influential probe sets from the kegg mapk pathway (a) and for the go-term mapkkk cascade (b) after stimulation with ra that contribute to the differential pathway expression in sos and control. probe sets are scaled to unit standard deviations and the height of the bars are the number of standard deviations above the cut-off level of 0.7. higher bars indicate higher influence on the pathway. probe sets with the highest influence on the pathway (i.e. fgf13 in figure 1a and tnik in figure 1b) are depicted on the left. corresponding gene names are written below each bar.,injury.24,25 these findings underline the need to investigate the roles of,(p < 0.05; figure 4) but not in the spinal cord,a. the predicted mir-382-5p targeting site within the rerg 3′utr and the mutated sites were aligned as indicated. b. after co-transfection with the mir-382-5p mimics or mnc, the relative luciferase activity of pmir-reporter carrying the wild-type or mutant rerg 3′utrs was determined in mcf-7 and hs578t cells and normalized to the empty vector transfectants. β-galactosidase control vector was also co-transfected and used as an transfection loading control. mir-382-5p mimics reduced luciferase activity in cells transfected with p-mir-reporter carrying the wild-type rerg 3′utr compared to mnc-transfected cells. there was no change in luciferase activity in cells co-transfected with mir-382-5p mimics or mnc with empty vector alone or p-mir-reporter carrying amutant rerg3′utr. c. the protein levels of ras/erk signaling members were determined using western blotting in mcf-7 and hs578t cells treated with the same conditions of figure 2a-2c. and mir-382-5p mimics dose-dependently reduced rerg expression and activated ras/erk signaling effectors, praf1, pmek1/2, and perk1/2 in mcf-7 cells, but mir-382-5p inhibitors dose-dependently resuced rerg expression and deactivated praf1, pmek1/2, and perk1/2 in hs578t cells. d. the bar-charts were used to show the relative protein levels which were normalized to gapdh and the ntc group was used as the comparative baseline (* p < 0.05, ** p < 0.01, *** p < 0.001, student t-test).,a and b. inhibition of tlr4 suppresses proliferation of ec109 cells. the viability and the level status of ki67 and pcna were detected using mtt assay and western blot analysis, respectively, 48 h after ec109 cells were transfected with specific sirnas targeting tlr4, myd88. *p < 0.05, **p < 0.01. c and d. inhibition of mapk pathways suppresses proliferation of ec109 cells. the viability and the level status of ki67 and pcna were detected using mtt assay and western blot analysis, respectively, 48 h after ec109 cells were transfected with specific sirnas targeting erk, jnk, and p38. *p < 0.05, **p < 0.01. e and f. inhibition of tlr4 induces apoptosis of ec109 cells. the apoptosis rates were determined using fcm analysis 48 h after ec109 cells were transfected with specific sirnas targeting tlr4, myd88. *p < 0.05, **p < 0.01. g and h. inhibition of mapk pathways induces apoptosis of ec109 cells. the apoptosis rates were determined using fcm analysis 48 h after ec109 cells were transfected with specific sirnas targeting erk, jnk, and p38. *p < 0.05, **p < 0.01.","pmc5537703,pmc5746140,pmc5127645,pmc5127645,pmc5127645,pmc5127645,pmc3498325,pmc6113736,pmc6113736,pmc5410235,pmc5190119",11,0.1,39,1,40.1
bcl-xl,protein,,bcl2l1,uniprot,q07817,mitochondria,go:0005739,apaf-1,protein,,apaf1,uniprot,o14727,mitochondria,go:0005739,negative,d,binds,,hek 293t,epithelial-like,kidney,human,"['18', '97', '136']","nan,nan,nan","nan,nan,nan","total rna was prepared using rneasy according to the manufacturer's protocol (qiagen, venlo, netherlands). reverse transcription pcr for the conversion of cdna was performed according to the recommended protocols for taqman,we made the following addition to the manuscript and included an extra supplemental figure:,a total of 31 mutations affecting genes of the ras-braf-mapk-erk pathway were observed in 30 of the 452 cll patients (7%) (online supplementary figure s1 and table 1). mutations were missense (25/31; 81%) or non-coding mutations at the 3′ or splice donor regions (6/31; 19%). the mean vaf for the 31 individual mutations was 0.36 ± 0.13. according to the results of the polyphen-2, sift and cadd algorithms used to predict the pathogenicity of the mutations, five mutations in the 3′ untranslated region (cases 1, 3, 11, 28 and 30) and one missense mutation (case 4, sos2 gene) were discarded as not being pathogenic. we were able to demonstrate that the mutation in the 3′ untranslated region of kitlg (case 1) was functional as we detected high levels of phosphorylated erk, a surrogate marker of ras-braf-mapk-erk pathway activation (figure 3a). due to the absence of cryopreserved material, we could not analyze the functionality of these mutations in the remaining cases. therefore, considering only the putative functional mutations, a total of 26 functional mutations affecting genes of the ras-braf-mapk-erk pathway were observed in 25 of 452 cll patients (5.5%). in 11 of the 25 patients (44%) these mutations were clonal (vaf ≥0.40) and in the other 14 patients (56%) they were subclonal (vaf <0.40). mutations were detected in genes upstream of braf (kitlg, kit, ptpn11, gnb1, kras and nras) in 12/452 patients (2.6%), in braf in 9/452 patients (2.0%), and in genes downstream of braf (map2k1 alias mek1, map2k2 alias mek2) in 5/452 patients (1.1%). the most frequent single mutated gene was braf (n=9/26, 34.6%) followed by ptpn11 (n=5/26, 19.2%), map2k2 (n=3/26, 11.5%), kras (n=3/26, 11.5%), and map2k1, (2/26 cases, 7.7%); mutations of gnb1, nras, kit, and kitlg were each found in one patient. one patient had concomitant mutations of ptpn11 and kras. interestingly, braf mutations were localized between exons 11 to 15 and most of them occurred in the activation loop (a-loop) near the v600 position or near the phosphate-binding loop (p-loop) at residues 464-469. only in one case did the braf mutation correspond to v600e, the most common mutation described in a variety of human malignancies including hcl.17","pmc5537703,pmc5127645,pmc6395334",3,0.1,39,1,39.3
p-erk,protein,,,uniprot,,,go:0005629,satellite cells,cell,,satl,uniprot,,cytoplasm,go:0005630,positive,d,increase,,,satellite cells,none,mouse,['158'],nan,nan,increase in p-erk in satellite cells and nonmyelinating schwann cells. the,pmc6113736,1,0.1,39,1,39.1
p-erk,protein,,prker2,uniprot,q96767,plasma membrane,go:0005886,astrocytes,cell,,,,,brain,go:0005624,positive,d,phosphorylation,,,brain,brain,mouse,['157'],nan,nan,of the number of p-erk-positive astrocytes/field of ipsilateral l5 drg.,pmc6113736,1,0.1,39,1,39.1
pbx3,protein,,pbx3,uniprot,q9y6z6,nucleus,go:0005739,hoxa9,protein,,hoxa9,uniprot,q9y6z6,nucleus,go:0005739,positive,d,binds,,,,,human,['179'],nan,nan,"pre-b-cell leukemia homeobox (pbx) refers to a family of transcription factors, including pbx1, pbx2 and pbx3. pbx3 has been continuously reported to be associated with tumor growth and progression. li et al. found pbx3 was an important cofactor of hoxa9 in leukemogenesis [14]. hoxa/pbx3 knockdown impaired leukemia growth and sensitized cells to standard chemotherapy [15]. recently, pbx3 was reported to be upregulated in gastric cancer and to regulate tumor cell proliferation [16]. han et al. demonstrated pbx3 promoted migration and invasion of colorectal cancer cells via activation of mapk/erk signaling pathway [17]. however, no data exist concerning the role of pbx3 in the progression of glioma. in addition, as a putative target gene of mir-320, whether mir-320 functions through regulating pbx3 remains unknown.",pmc5609034,1,0.1,39,1,39.1
nsd1,protein,set domain protein,nsd1,uniprot,q92674,nucleus,go:0005634,nuclear hormone receptors,other,,,fplx,,plasma membrane,go:0005886,positive,d,methyltransferase activity,,,,,human,['123'],nan,nan,"sotos syndrome (sos; mim 117550) is characterized by tall stature, facial dysmorphism and mental retardation [1]. it is caused by haploinsufficiency of the nuclear receptor binding set domain protein 1 (nsd1) gene [2]. originally, mouse nsd1 was identified in a two-hybrid screen with the retinoic acid receptor alpha (rarα) as bait [3]. it was shown that nsd1 interacted with a number of nuclear hormone receptors, such as the estrogen receptor, retinoic acid and thyroid hormone receptors [3]. it was postulated that nsd1 could either act as a co-repressor or a co-activator of these nuclear receptors depending on the cellular context and the presence or absence of the respective hormones [3]. since then, several in vitro experiments showed that an important function of nsd1 is the methyltransferase activity of its su(var)3–9, enhancer-of-zeste and trithorax (set) domain [4]–[6]. this domain specifically methylates lysine 36 at histone h3 (h3-k36), lysine 20 at histone h4 (h4-k20) and other non-histone substrates (4-7), resulting overall in the regulation of chromatin transcription. for example, nsd1 was shown to regulate activity of the transcription factor nf-κb [7]. furthermore, depletion of nsd1 reduced the expression of the bone morphogenetic protein gene 4 (bmp4) [5]. in addition, a fusion protein nup98–nsd1 which is found in about 5% of human acute myeloid leukemia patients, was demonstrated to regulate transcription of the hox-a gene locus [8]. in a tissue-specific manner nsd1 exhibits both repressing as well as activating capacities as was exemplified by reduced expression of the meis1 oncogene in a neuroblastoma model, while increased expression was detected in transfected cells containing the nup98–nsd1 fusion protein [8], [9].",pmc3498325,1,0.1,39,1,39.1
nras,protein,,nf1,uniprot,q92579,cytoplasm,go:0005739,tumor,disease,,,fplx,tumor,cytoplasm,go:0005739,negative,d,mutation,,,,,human,['61'],nan,nan,"for nras, there are 8 tumor types that meet our selection criteria (5 or more mutated samples). because of a historical issue, the data for coad and read are divided into 2 sequencing platforms for expression analysis (illumina hiseq [hs] and illumina ga). they are as follows: skcm, coad (ga and hs), read (hs and ga), acute myelogenous leukemia (laml), tgct, thca, blca, and ucec. of these tumor types, skcm (where nras has a presumed driver role) and read (both in ga and hs) showed a significant increase in the nras-mutant sample subset relative to the wt subset (figure s3a). although not significant, the trend is also apparent in the coad samples from both platforms. a weaker trend is present in the blca and ucec tumor types (figure s3b), but not in the tgct, thca (where nras mutation is considered a driver event) and laml sample subsets (figures s3a and b).",pmc5467702,1,0.1,39,1,39.1
oncogenic ras,protein,oncogene,hras,uniprot,q92579,cytoplasm,go:0005634,interferon (ifn) signaling,signalingpathway,,,uniprot,,cytoplasm,go:0005634,positive,d,inhibition,,nih/3t3,fibroblast,,mouse,['34'],nan,nan,"oncolytic viruses exploit alterations in cancer cells to specifically infect cancer cells but not normal healthy cells. previous work has shown that oncogenic ras interferes with interferon (ifn) signaling to promote viral replication. furthermore, inhibition of the ras/raf/mek/erk pathway at the level of ras, mek, or erk was sufficient to restore ifn signaling. in order to identify genes that were commonly regulated by the inhibition of the ras pathway and the ifn pathway, we treated nih/3t3 cells that overexpress oncogenic ras with the mek inhibitor, u0126, or ifn-α for 6 h, and performed dna microarray analysis (gene expression omnibus accession number gse49469). here, we also provide additional information on the experimental and functional analysis of the genes responsive to u0126 and ifn.",pmc4535867,1,0.1,39,1,39.1
p75ntr,protein,neurotransmitter receptor,ntrn1,uniprot,q07817,plasma membrane,go:0005886,cd11b,protein,integrin,itga1,uniprot,o14727,plasma membrane,go:0005886,positive,d,binds,,,microglia,brain,mouse,['156'],nan,nan,"improve neurological function after brain injury.33,34 the double staining was",pmc6113736,1,0.1,39,1,39.1
other,protein,,,uniprot,,,,tcr,other,,,fplx,tcr,,,negative,d,binds,,,b-cell,,vein,['96'],nan,nan,"in addition, the authors should consider the other, less major, comments that are listed below.",pmc5127645,1,0.1,39,1,39.1
nps,other,,,uniprot,,,,microglia,cell,,cd11b,uniprot,p00325,immune system,go:0005655,positive,d,activated,,,immune cell,,,['161'],nan,nan,"ligated, resulting in the primary damage to the nerve.40 this initiated a cascade of inflammatory reactions in the spinal cord, and np",pmc6113736,1,0.1,39,1,39.1
affy_ff,other,,,,,,,affy_ffpe,other,,,,,,,positive,d,correlation,,,,,,['32'],nan,nan,"as shown in table 1b, the removal of 15 “outlier” samples resulted in increases in three pairwise correlations among affy_ff vs. [1] affy_ffpe, [2] nanos_ffpe and [3] rna-acc_ffpe. notably, the correlation between affy_ff and affy_ffpe changed from being insignificant (r = 0.233, p = 0.090) to significant (r = 0.556, p = 0.0002).",pmc5069826,1,0.1,39,1,39.1
peripheral,other,,,uniprot,,,,central,other,,,uniprot,,,,negative,d,binds,,,,,human,['149'],nan,nan,"diminishing both peripheral and central sensitization.19–21 however, the cellular and",pmc6113736,1,0.1,39,1,39.1
rna,nucleicacid,,,uniprot,,cytoplasm,go:0005632,melanoma,cancer,,,uniprot,,cytoplasm,go:0005632,positive,d,hybridization,,,,,human,['33'],nan,nan,"the poor quality of rna extracted from ffpe samples is thought to result from fixing procedures that cause rna cross-linking and from rna degradation over time in ffpe blocks depending on storage temperature [20, 21, 35–38]. while lebbe and co-workers used the expression levels of a set of reference genes to construct a statistic for differentiating “bad” melanoma samples from “good” ones [36], sfakianos et al. used pca analysis to identify “bad” samples in ovarian cancer ffpe samples [19]. we adopted the pca method to identify and filter out 15 “outlier” samples with “poor” rna quality. the removal of the “outlier” samples improved the correlations of affy_ff (as a “gold” standard) significantly with affy_ffpe, but only slightly with nanos_ffpe; the 15 “outlier” samples identified for the affy_ffpe platform did not appear to be outliers for nanos_ffpe. a plausible explanation is that in contrast to affymetrix and rnaseq technologies, nanostring is a more “direct” technology (hybridization-based) to detect the number of rna transcripts, so it does not need steps of mrna reverse-transcription into cdna and subsequent cdna amplification. reverse-transcription and cdna amplification are known to be sensitive to the rna quality issue caused by rna cross-linking in ffpe samples.",pmc5069826,1,0.1,39,1,39.1
tlr4,receptor,,tlr4,uniprot,q92769,plasma membrane,go:0005886,myd88,protein,,myd88,uniprot,q92768,plasma membrane,go:0005886,positive,d,binds,,,,,human,['191'],nan,nan,"a recent study highlighted that activation of tlr4 by paclitaxel enhances tumor growth and metastasis in breast cancer, and that blocking paclitaxel-induced tlr4 activation in cancer may observably improve therapeutic outcome. [36]. activation tlr4 by lps significantly enhanced survival of prostate cancer cells while tlr4 inhibition by a specific inhibitor led to rapid death of prostate cancer cells, [37]. toll-like receptor 4 (tlr4) has been shown to be upregulated in esophageal squamous cell carcinoma [38]. tlr4 is associated with lymph node metastasis, and stimulation of tlr4 with lps has been displayed to accelerate migration and adhesion of esophageal squamous cell carcinoma cells [15, 38]. in the present study, we also observed that lps increased expression levels of tlr4, myd88, and traf6, whereas pparγ agonist rgz resisted this effect. we deduced that pparγ agonist rgz inhibited progression of esophageal cancer cells via blocking tlr4 pathway in our system. previous studies demonstrated that pparγ agonist rgz suppressed the expression of tlr4 mrna and protein in alveolar macrophages [25] and that pparγ agonist pioglitazone attenuated angiotensinii-induced inflammatory response in cardiac fibroblast cells through inhibition of the tlr4 signaling pathway [39], which are consistent with our study.",pmc5190119,1,0.1,39,1,39.1
the cancer genome atlas (tcga) project,organization,,,uniprot,,,go:0005739,cancer,disease,,,uniprot,,,go:0005739,positive,d,data-mining,,,,,human,['59'],nan,nan,"as one of the largest public repositories of cancer genomic data, the cancer genome atlas (tcga) project has produced a wealth of new insights into cancer biology and the underlying driver events that give rise to the disease (see http://cancerge-nome.nih.gov/abouttcga/overview). the cancer genome atlas data are publicly available and contain very broad data modalities spanning many different genomic platforms and associated patient clinical information and as such represent a considerable data mining resource. to date, several detailed integrative analyses of data from many of the individual tumor types have been reported (see https://tcga-data.nci.nih.gov/docs/publications/ and http://cancergenome.nih.gov/publications). in addition, a series of reports have detailed “pan-cancer” analyses where data aggregated across many tumor types and genomics platforms were used to identify similarities and differences among and between different tumor types (http://www.nature.com/tcga/). to more directly benefit the ras community, a ras gene–specific survey is desperately needed.",pmc5467702,1,0.1,39,1,39.1
tgn-020,drug,,,uniprot,,,,endogenous cannabinoid signaling,biologicalprocess,,cb1,uniprot,p00627,plasma membrane,go:0005886,negative,d,inhibition,,,,,human,['162'],nan,nan,antinociceptive effect of tgn-020 might possibly be related to the suppression of,pmc6113736,1,0.1,39,1,39.1
tgn-020,drug,,,uniprot,,,,cannabinoid receptor 1 (cb1),protein,,cb1,uniprot,p00500,plasma membrane,go:0005886,negative,d,inhibition,,,,,,['163'],nan,nan,supplemental material for correlation of tgn-020 with the analgesic effects via,pmc6113736,1,0.1,39,1,39.1
tgn-020,drug,,,uniprot,,,,aqp4,protein,,aqp4,uniprot,p00789,plasma membrane,go:0005886,negative,d,inhibits,,,,,human,['160'],nan,nan,the present study showed that aqp4 inhibitor tgn-020 could exert a remarkable,pmc6113736,1,0.1,39,1,39.1
tgf-β/smad signaling pathway,signalingpathway,,,uniprot,,,,tgf-β1,protein,,tnfbsf2,uniprot,q02805,extracellular space,go:0005739,negative,d,inhibition,,,,lung,mouse,['154'],nan,nan,"7, 14, and 21 days after injury compared with that in the sham group. tgn-020",pmc6113736,1,0.1,39,1,39.1
sirt1,protein,,sirt1,uniprot,q9hz75,cytoplasm,go:0005634,"mapk (erk, jnk, p38mapk)",proteincomplex,,mapk,uniprot,q96ja7,cytoplasm,go:0005634,positive,d,phosphorylation,,,astrocyte,,mouse,['132'],nan,nan,"thus, we hypothesize that both the sirt1 and mapk pathways, such as erk, jnk, and p38, were involved in regulating the astrocyte activation, and some networks through yet unknown mechanisms promote the recovery of neural function via attenuation of the astrocyte activation. to test this hypothesis, we applied a nigrostriatal pathway injury in the mouse brain to mimic the traumatic brain injury in vivo and il-1β stimulation model to induce astrocyte activation in vitro. based on these in vitro and in vivo models, we analyzed the expression of sirt1 and p-erk, p-jnk, and p-p38 after stimulation or injury and monitored gfap expression and astrocytes hypertrophy, as well as the interactions between sirt1 and mapk (erk, jnk, p38mapk) pathways after manipulation of sirt1 and p-erk, p-jnk, and p-p38 levels pharmacologically and genetically.",pmc5372348,1,0.1,39,1,39.1
siah,protein,,siah,uniprot,q9h1g9,cytoplasm,go:0005739,her2/egfr/k-ras,signalingpathway,,,fplx,her2/egfr/k-ras,plasma membrane,go:0005886,positive,d,expression,cytoplasm,,cancer,,human,['184'],nan,nan,"as a major tumor-promoting pathway, ras pathway activation/inactivation is ideally positioned to serve as a therapy-responsive, tumor heterogeneity-independent, and growth-dependent prognostic biomarker in breast cancer. here, we conducted a retrospective study to determine whether the ras pathway biomarkers can be added to evaluate tumor response and therapy efficacy, forecast patient survival, and predict which patients with invasive breast cancer are likely to benefit from standard nst regimens, or which patients will benefit from additional regimens after ineffective first-line therapies are identified. siah function is required for proper her2/egfr/k-ras signal transduction, cancer cell proliferation and survival (schmidt et al., 2007, ahmed et al., 2008, qin et al., 2015, tang et al., 1997, adam et al., 2015). siah is expressed in proliferating tumor cells. we have previously associated increased siah expression with the progression of ductal carcinoma in situ (dcis) to invasive carcinoma (behling et al., 2010). we showed that combining five molecular biomarkers (egfr, siah, phospho-erk, ki67 and hif1α) in the oncogenic k-ras/ki67/hif1α pathways, with four clinicopathological predictors can be used to predict patient survival post surgery in human pancreatic cancer (qin et al., 2015). other groups have shown that siah expressed in breast cancer (wright et al., 2015, palmieri et al., 2009, bruzzoni-giovanelli et al., 2010, confalonieri et al., 2009, chan et al., 2011). importantly, we were the first group to demonstrate the efficacy of an anti-siah-based anti-k-ras and anticancer strategy to shutdown the “undruggable” oncogenic k-ras activation and successfully block oncogenic k-ras-driven tumorigenesis in several animal models of human cancer (schmidt et al., 2007, ahmed et al., 2008, van sciver et al., 2016, wong and moller, 2013).",pmc5049993,1,0.1,39,1,39.1
selumetinib,drug,inhibitor,krasg12c,uniprot,q9yt57,plasma,go:0005886,t cells,cell,,,uniprot,tcr,plasma membrane,go:0005886,positive,d,inhibition,plasma membrane,,t-cell,,human,['31'],nan,nan,"safety data have demonstrated that selumetinib overall appears to be well-tolerated. the most common adverse events were rash (63%–74% of patients) and fatigue (41%–68% of patients) in a dose-dependent manner in phase 1 studies.32,33 selumetinib-induced skin reactions have been evaluated in patients with advanced melanoma in a phase 2 study.58 the most common acute skin reaction was papulopustular rash on the face, upper chest, and back with increased apoptotic keratinocytes and focal neutrophil infiltration histologically. in a half-side treatment experiment, one side of the face of all patients was treated with topical corticosteroid and the other side with topical antibiotics. a faster improvement of the selumetinib-associated skin reactions was observed with topical steroid than antibiotics, which suggests an inflammatory component of the rash caused by neutrophils. diarrhea and nausea, the two most common gastrointestinal toxicities, have been reported in 48%–61% and 44%–54% of the patients, respectively.32,33 these toxicities were generally responsive to supportive care. peripheral edema, reversible mild to moderate transaminitis, and transient and reversible blurry vision have been reported as adverse events as well. hematologic toxicity is a rare toxicity with selumetinib. grade 3/4 toxicities were reported up to 71% in a phase 1 study, but the majority of the toxicities were reported by only a single patient each. grade 3/4 events reported by more than one patient were left ventricular dysfunction, nausea, vomiting, fatigue, febrile infection, pneumonia, elevation of alkaline phosphatase, elevation of γ-glutamyltransferase, hypoxia, dyspnea, abdominal pain, constipation, anemia, rash, and hypertension.32–34",pmc4179759,1,0.1,39,1,39.1
selumetinib,drug,inhibitor,araf,uniprot,q92776,plasma,go:0005886,araf,protein,,araf,uniprot,p01730,plasma membrane,go:0005886,negative,d,inhibits,,,,,human,['30'],nan,nan,"the results of the phase 2 studies and ongoing clinical trials of selumetinib are summarized in tables 1 and 2, respectively.",pmc4179759,1,0.1,39,1,39.1
selumetinib,drug,braf inhibitor,kras,uniprot,q9y2h4,plasma,go:0005886,braf v600e mutant metastatic melanoma,disease,,,uniprot,,none,,negative,d,inhibition,,,,none,human,['28'],nan,nan,"in a phase 1 study of selumetinib hyd-sulfate oral capsule, 75 mg twice a day was established as the mtd dose, as previously described.33 one complete response of braf v600e mutant metastatic melanoma (2.9%) and 16 stable disease (45.7%) were observed among 35 patients with advanced solid tumors who received 75 mg twice a day of selumetinib.33 because this study demonstrated a better pharmacokinetic profile of the hyd-sulfate formulation than the freebase formulation, as discussed earlier, subsequent studies have used the hyd-sulfate formulation of selumetinib.",pmc4179759,1,0.1,39,1,39.1
rgz,smallmolecule,,,uniprot,,,,tlr4,protein,,tlr4,uniprot,q96268,plasma membrane,go:0005886,negative,d,inhibition,,ec109,b-cell,,mouse,['188'],nan,nan,"ec109 cells were pretreated with rgz (20 μm) or gw9662 (10 μm) overnight, and then stimulated with 10 ng/ml of lps or vehicle for 1 h. tlr4, myd88, and traf6 expression levels were detected using western bolt analysis. *p < 0.05, **p < 0.01.",pmc5190119,1,0.1,39,1,39.1
pi,dye,non-permeable,,uniprot,,,,organoid,cell,,,uniprot,,,,negative,d,binds,,,,,,['90'],nan,nan,"of note, this method is independent of non-permeable dna dyes such as pi to avoid their potential long-term effect on organoid growth. in order to validate the current method, a single time point data set was acquired with the use of pi (see figure 7—figure supplement 1), validating the robustness of the strategy.",pmc5127645,1,0.1,39,1,39.1
rerg,protein,,rrg,uniprot,q92576,cytoplasm,go:0005739,ras/erk pathway,signalingpathway,,,uniprot,go:0007166,plasma membrane,go:0005886,positive,d,binds,,breast cancer cell,epithelial,breast,human,['166'],nan,nan,"aberrant activation of the ras/erk pathway mediates breast cancer initiation and aggressiveness. therefore, it is important to identify mirnas that modulate the ras/erk pathway during breast carcinogenesis and progression. the ras gtpase superfamily member rerg (ras-related and estrogen-regulated growth inhibitor) acts as a tumor suppressor to reduce breast cancer cell proliferation and tumor formation and has been suggested to have a regulatory role in the ras/erk pathway. in this study, we found that rerg exerted its tumor suppressor role by attenuating the activation of ras/erk signaling effectors. furthermore, we found that mir-382-5p directly targets and represses rerg to attenuate the inhibitory effects of rerg on the oncogenic ras/erk pathway. thereby, mir-382-5p promoted breast cancer cell viability, clonogenicity, survival, migration, invasion and in vivo tumorigenesis/metastasis. in clinical interpretation, mir-382-5p expression was negatively correlated with rerg expression, and it also significantly functioned as an independent oncomir for the higher incidence and poorer prognosis of breast cancer. this novel connection highlights new diagnostic and prognostic roles for mir-382-5p and rerg in breast cancer.",pmc5410235,1,0.1,39,1,39.1
rdm1,protein,,rdm1,uniprot,q9y6z7,cytoplasm,go:0005634,nb,disease,,,uniprot,nb,,,negative,d,inhibition,,,,,human,['64'],nan,nan,"given the potential role of rdm1 in the dna repair pathways, we found that rdm1 is up‐regulated in nb patient samples and the up‐regulation of rdm1 is correlated with poor clinical prognosis. moreover, we investigated the effect of rdm1 on nb cell growth, cell apoptosis and the cell cycle. we further evaluated the in vivo growth of rdm1‐knockdown cells in a mouse xenograft model. interestingly, knockdown of rdm1 inactivated the ras–raf–mitogen‐activated protein kinase kinase (mek)–extracellular signal‐regulated kinase (erk) signaling pathway. taken together, our findings present a novel insight into the oncogenic role of rdm1 in the development of nb.",pmc6396142,1,0.1,39,1,39.1
rdm1,protein,,rdm1,uniprot,q9y6j8,cytoplasm,go:0005739,nb cell,other,,,uniprot,nb cell,cytoplasm,go:0005739,negative,d,knockdown,,,mammary epithelial,breast,mouse,['65'],nan,nan,"previous work showed the regulation of rdm1 in lung cancer 16 and papillary thyroid carcinoma 17. however, in this study, we identified rdm1 as an oncogenic target in nb. firstly, we found knockdown of rdm1 could reduce nb cell proliferation, augment cell apoptosis and induce cell cycle arrest. furthermore, the xenograft mouse model showed stable knockdown of rdm1 significantly inhibits nb tumor growth. these results served as direct evidence that rdm1 might be of benefit for cancer cell survival. studies of the role of dna repair in the maintenance of genome integrity in mammalian cells have provided insight into the molecular aspects in cancer 23, and incorrectly repaired dsbs could cause mutations or chromosome rearrangements and result in cancer progression 24. our finding of the increased cell apoptosis and cell cycle arrest in sirdm1 cells provides a potential mechanistic basis for the impaired dsb response. future work should define whether ddr pathways will be altered in the context of manipulating rdm1.",pmc6396142,1,0.1,39,1,39.1
rasip1,protein,,rasip1,uniprot,q92553,endosomes,go:0005739,nsd1,protein,,nsd1,uniprot,q96773,nucleus,go:0005739,positive,d,binds,,,b-cell,,vein,['130'],nan,nan,"the second independent line of evidence for an association with the mapk/erk kinase signaling pathway was derived from the limma analysis, which identified rasip1 as the number 1 differentially expressed gene between sos and control. knock down experiments confirmed rasip1 as a direct target of nsd1. rasip1 interacts in a gtp-dependent manner with endomembrane-associated ras and is recruited to the golgi by activated ras (ras-gtp) [21]. rasip1 binds to several members of the ras family and is proposed to be a downstream ras-effector, which is a central player in the mapk/erk pathway [21]. the physiological significance of such compartmentalized signaling of ras, i.e. ras signaling on endosomes such as endoplasmic reticulum and the golgi apparatus, has not been elucidated yet [32]. since it was shown that golgi-associated ras was able to activate the mapk signaling cascade in a timely and quantitatively different manner, it was proposed that compartmentalized ras signaling would increase the complexity of possibilities for downstream signaling [33]. therefore, increased rasip1 expression in interference with activated ras, might be related to the differences in cell growth and differentiation observed in sos.",pmc3498325,1,0.1,39,1,39.1
ras pathway,signalingpathway,,,uniprot,,plasma membrane,go:0005886,,,,,,,,,positive,d,mutation,,,,,human,['194'],nan,nan,nan,nan,1,0.1,39,1,39.1
ras pathway,signalingpathway,,,uniprot,,plasma membrane,go:0005886,all,disease,,,uniprot,,,,positive,d,mutation,intragenic deletion of nf1,,,,human,['103'],nan,nan,"mutations in the ras pathway clearly show a strong correlation with specific cytogenetic subgroups of all and are prevalent in both very poor and very good risk cytogenetic groups, which may neutralize any effect on prognosis when a patient cohort is analyzed as a whole. for example, ras pathway mutations are consistently associated with high hyperdiploidy, which represents a third of all newly diagnosed children and confers a very favorable prognosis (13, 15, 16, 19, 32, 72, 76). reported incidences of ras pathway mutations in this subgroup range from 24% to almost 60%, with a large study reporting mutations in 30% compared to 10% in non-hyperdiploid cases (16). they also occur at high frequency in the context of hypodiploid all (23). hypodiploidy (<45 chromosomes) occurs in around 5% of call cases and is associated with a very poor prognosis (77). hypodiploidy can be further divided by karyotype into three distinct groups, near-haploid (23–29 chromosomes), low hypodiploidy (33–39 chromosomes), and high hypodiploidy (42–45 chromosomes). more than two-thirds of near-haploid cases feature mutations predicted to result in aberrant ras signaling, in particular intragenic deletion of nf1 (23). enhanced signaling has been demonstrated in low hypodiploid cases in the absence of known canonical ras pathway mutations, suggesting that additional mechanisms of pathway activation remain to be identified in this subgroup (23). one possible mechanism is the deregulated expression of a microrna, mir335 that targets and regulates levels of erk2 (78). the high prevalence of pathway mutations in aneuploid leukemias is notable and there is evidence of a possible link between deregulated signaling through the ras pathway and chromosomal instability (79). ras pathway mutations have also been identified at high incidence in cases defined as “high risk” and also in the very aggressive, etp all (24, 25). in addition, poor risk chromosomal translocations, including bcr/abl and those involving the mll locus are associated with constitutive activation of the ras pathway (55–57). interestingly, ras pathway mutations are rare in the etv6–runx1 cytogenetic subgroup (10, 15).",pmc4067595,1,0.1,39,1,39.1
pparγ agonist,drug,,pparg,uniprot,q00542,cytoplasm,go:0005739,mapk pathway,signalingpathway,,,uniprot,mapk,cytoplasm,go:0005739,negative,d,inhibits,,esophageal cancer cells,cancer,,human,['189'],nan,nan,pparγ agonist inhibits the mapk pathway in esophageal cancer cells,pmc5190119,1,0.1,39,1,39.1
pparγ,protein,,pparg,uniprot,q17699,plasma membrane,go:0005886,rxrα,protein,,rxra,uniprot,q03773,plasma membrane,go:0005886,positive,d,heterodimerization,,ec109,epithelial,,human,['187'],nan,nan,"transcriptional regulation by ppars requires heterodimerization with rxr [23]. pparγ and rxrα form a non-symmetric complex, allowing the ligand-binding domain of pparγ to link multiple domains to both proteins [24]. we observed that sirna-mediated knockdown of rxrα in ec109 cells blunted the ability of rgz to repress cell proliferation (figure 1e). to further confirm the role of pparγ, western blot analysis was conducted to detect the expression status of ki67 and pcna. the expression levels of ki67 and pcna were decreased in response to pparγ activation in ec109 and te10 cells (figure 1b and 1d), but increased in the presence of gw9662 or when knockdown of pparγ or rxrα (figure 1f). taken together, all these findings suggest that pparγ is acting as a heterodimer with rxrα to suppress proliferation of esophageal cancer cells.",pmc5190119,1,0.1,39,1,39.1
plink,software,,,uniprot,,,go:0005886,snp,other,,,fplx,,,go:0005886,negative,d,--,,,,,human,['78'],nan,nan,"manipulation of the set of genotypes and statistical analyses were performed using plink 1.9 [23]. the exact test was used to detect departures from the hwe. a logistic regression analysis was performed to assess association of snps under the allele (additive), dominant, co-dominant, and recessive models. fisher’s exact test of independence was used to compare genotype distribution between cases and controls. to infer population stratification, we used the set of genotypes obtained from infinium global screening array (illumina, ca, usa) excluding—pruning—snps from extended regions of high ld (r2 > 0.2) using --indep–pairwise in plink 1.9. a final set of 184,909 autosome snps were submitted for principal component analysis (pca) using --pca in plink 1.9. principal component (pc)1 and pc2 were included in the logistic regression analyses as covariates to obtain p-values adjusted for population stratification [24]. false discovery rate (fdr) was used to correct for multiple testing according to the benjamini–hochberg procedure [25]. the cutoff of the fdr adjusted p-value (q-value) was 0.05. we computed the power for genetic association under the allele model using quanto 1.2.4. (http://biostats.usc.edu/quanto.html).",pmc6356706,1,0.1,39,1,39.1
pi3k/akt,pathway,,,uniprot,,,,cellular processes,,,,uniprot,,,,negative,d,regulation,,,,,human,['27'],nan,nan,"to overcome the inconsistent efficacy of selumetinib and enhance its antitumor activity, several combinatorial approaches have been studied. the combined treatment with selumetinib and cytotoxic chemotherapy such as irinotecan, docetaxel, temozolomide, and doxorubicin resulted in significant enhanced antitumor efficacy by both cell cycle arrest and apoptosis in mice xenografts of braf mutant melanoma, as well as kras mutant colon cancer, non-small-cell lung cancer, pancreatic cancer, and hepatocellular carcinoma.17,18,20,21 gopal et al have reported that the pi3k/akt pathway plays a critical role in the antitumor efficacy of selumetinib in braf mutant melanoma, and inhibition of pi3k/akt pathway results in synergistic antitumor activity with selumetinib.22 because it has been reported that activation of wnt/β-catenin signaling pathway inhibits tumor growth in mouse models of melanoma,23 the combinatorial effect of wnt/β-catenin activation and selumetinib was examined.24 the combination of selumetinib and wnt3a, a ligand of wnt/β-catenin pathway, induced apoptosis of melanoma cell lines harboring braf or nras mutations by degradation of axin1, a negative regulator of wnt/β-catenin signaling.24 apoptosis-resistant braf and nras mutant melanoma cell lines were able to sensitize to selumetinib by knock-down of axin1 expression with sirna in the study.24",pmc4179759,1,0.1,39,1,39.1
pi,dye,non-permeable,,uniprot,,,,organoid,cellaggregate,,,uniprot,,,,negative,d,binds,,,,,,['98'],nan,nan,"“of note, this method is independent of non-permeable dna dyes such as pi to avoid their potential long-term effect on organoid growth. in order to validate the current method, a single time point data set was acquired with the use of pi (see figure 7—figure supplement 1), validating the robustness of the strategy.”",pmc5127645,1,0.1,39,1,39.1
nf1,protein,,nf1,uniprot,q02305,cytoplasm,go:0005739,lid,disease,,,,,,,negative,d,reduces,,,,,mouse,['165'],nan,nan,"to explore the role of nf1 in dyskinesia, we studied the development of lid in hemiparkinsonian/6-ohda-lesioned mice by scoring axial dystonia and forelimb and orofacial dyskinesias in nf1+/− and their wt littermates. since high l-dopa doses can mask subtle differences between genotypes, we used an escalating dosing regimen in which l-dopa was given i.p. daily for 9 days, with the daily dose increasing over the course of treatment (5, 10, and 20 mg/kg i.p., 3 consecutive days at each dose).",pmc6194127,1,0.1,39,1,39.1
mapk/erk signaling pathway,signalingpathway,,,uniprot,,,go:0005886,dermal fibroblasts,celltype,,,uniprot,,,go:0005886,negative,d,deregulation,,,b-cell,,human,['127'],nan,nan,"in order to elucidate biological pathways explaining how nsd1 haploinsufficiency results in phenotypic features such as overgrowth in sos a comprehensive study of dermal fibroblasts from sos patients was performed. we obtained evidence that sos syndrome is associated with a deregulation of the mapk/erk signaling pathway. the mapk/erk signaling pathway is an important regulator of cell differentiation, proliferation and apoptosis [24]. more recently, activating mutations in this pathway have been identified as the causative factor in a number of short stature syndromes, such as noonan syndrome and costello syndrome [25].",pmc3498325,1,0.1,39,1,39.1
ndk-1,protein,,ndk1,uniprot,p13970,plasma membrane,go:0005886,ksr-2,protein,,ksr2,uniprot,q96ja3,plasma membrane,go:0005886,positive,d,direct interaction,,,,,somatic tissues,['9'],nan,nan,"our group has recently characterized ndk-1, the c. elegans homolog of group i ndpks, and we provided a compelling case that ndk-1 affects ras/mapk signaling at the level of ksrs, and first demonstrated a functional interaction between ndk-1/ndpk and ksrs in vivo[18]. however, genetic and biochemical data demonstrate reduced mapk signaling in somatic tissues of ndk-1 knockouts, therefore we conclude that ndk-1 is necessary for proper mapk activation, thus ndk-1/ndpk exerts a stimulatory effect on ras/mapk signaling [18]. since ndk-1 directly interacts with ksr-2 and with murine ksr1, we consider it likely that ndk-1 modifies the function of ksr scaffolds.",pmc4020307,1,0.1,39,1,39.1
dmso,solvent,,,uniprot,,,,rat,organism,,,uniprot,,,,negative,d,binds,,,none,none,rat,['152'],nan,nan,"four days after injury, the rats were euthanized and perfused intracardially with",pmc6113736,1,0.1,39,1,39.1
nabut,compound,drug,,uniprot,,plasma membrane,go:0005886,pd0325901,compound,drug,,uniprot,,plasma membrane,go:0005886,negative,d,inhibits,,,,,human,['15'],nan,nan,"cells were seeded at the initial density of 3×104 cells per 35 mm cell culture dish (costar, usa) in 3 repeats 24 h before the treatment. cells were treated with nabut and pd0325901 or left untreated. the medium was replaced by a fresh one supplemented with 10% fbs and inhibitors every second day. the number of cells was daily counted in the cell counting chambers throughout 120 h. the growth curves were plot based on the data obtained in 3 independent experiments.",pmc5723691,1,0.1,39,1,39.1
gc1q,protein,,q9bxa8,uniprot,q9bxa8,plasma membrane,go:0005886,hacat cells,cell,,,,,cytoplasm,go:0005886,negative,d,binds,,hacat,epithelial-like,,mouse,['122'],nan,nan,"hacat cells were starved in dmem without fcs and then harvested by trypsinization and incubated in complete medium for 1 hour at 37°c. cells were then washed in dmem without fcs, resuspended in dmem and plated for 24 hours on a 96 well plate previously coated with gc1q or polylysine in the presence or in the absence of dmso. the following day, the cells were loaded with 5 mm fluo-4 am (invitrogen) in dmso according to the manufacturer's instructions. fluorescence intensity of the time lapse images was acquired every 45 min during a period of 6 hours using the af6000 lx workstation leica.",pmc5432316,1,0.1,39,1,39.1
gc1q,protein,,c1qbp,uniprot,q92578,plasma membrane,go:0005886,α4 integrin,protein,,itga4,uniprot,q07725,plasma membrane,go:0005886,negative,d,binds,,,epithelial-like,,human,['120'],nan,nan,the gc1q ligated α4 integrin chain is physically linked to hras and controls cell growth,pmc5432316,1,0.1,39,1,39.1
erk1/2,protein,,mapk1/3,uniprot,q92079,cytosol,go:0005739,ras/mek/erk,signalingpathway,,,uniprot,ras/mek/erk,cytosol,go:0005739,positive,d,activates,,,embryonic stem cells,,human,['111'],nan,nan,"the extracellular signal‐regulated protein kinases 1 and 2 (erk1/2) belong to the mitogen‐activated protein kinase (mapk) super family that transmit signals from various cell surface receptors to cytosolic and nuclear targets 5. in a variety of cell types, the activation of ras/mek/erk cascade leads to promoting the cell proliferation and survival 6, 7, 8. however, this is not the case for all cell types. remarkably, the erk1/2 signalling is dispensable for proliferation and self‐renewal of embryonic stem cells, whereas there is dependency on erk upon lineage commitment 9, 10.",pmc5824365,1,0.1,39,1,39.1
"erk1,2",protein,,mapk3/1,uniprot,p00779,cytoskeleton,go:0005629,nabut,drug,,,uniprot,q9y2a4,plasma membrane,go:0005886,positive,d,phosphorylation,,hek 293t,epithelial-like,kidney,human,['11'],nan,nan,"(a) western-blot analysis of erk1,2 phosphorylation after short-term (2 h) and long-term (24 h-120 h) nabut, nabut+pd and pd treatment. cells were cultivated with inhibitors for the indicated time and then lysed and processed to western-blotting in 12% gel. numbers below present densitometry of bands. (b) growth curves of cells after exposure to inhibitors. the number of cells was counted after 24, 72 and 120 hours of experiment. data are presented as mean ±s.e.m. of three independent replicates (n=3). (c) clonogenic viability and proliferative potential of cells after removing the inhibitors. cells were cultivated with inhibitors for 72 h and 120 h and then seeded at 200 cells per 30mm dish in drug-free medium. clones were stained with crystal violet after 7 days of growth. data are presented as mean ±s.e.m. of three independent replicates (n=3). for regrowth assay, cells were treated with inhibitors for indicated time and then provided with fresh inhibitor-free medium. clones were stained crystal violet after 5 days of growth in fresh media and counted. (d) cell cycle distribution after exposure to inhibitors was analyzed by flow cytometry of propidium iodide-stained cells. percentage of cells in g1, s and g2 phase indicated. (e) viability was analyzed by mtt-test, amount of formazan was measured at 570 nm wavelength. data are presented as mean ±s.e.m. of three independent experiments (n=3).",pmc5723691,1,0.1,39,1,39.1
erk/map-kinase,protein,,mapk1/3,uniprot,q04105,plasma membrane,go:0005886,melanoma cell,other,,,,,,,positive,d,activates,,,,,melanoma,['73'],nan,nan,the discovery of the relevance of erk/map-kinase signaling for melanoma,pmc4846800,1,0.1,39,1,39.1
erk pathway,signalingpathway,,,uniprot,,plasma membrane,go:0005886,tnbc,disease,,,uniprot,,,,negative,d,inhibition,,,,,human,['45'],nan,nan,"triple negative breast cancer (tnbc) is not sensitive to ras/raf/erk signaling pathway (erk pathway) targeting therapy, due to the absence of excessive activation of erk pathway. however, the kinase cascades might be activated after chemotherapy in tnbc. here we aimed to predict whether erk pathway targeting therapy could be used as an adjuvant therapy in tnbc.",pmc5746140,1,0.1,39,1,39.1
erk 1/2,protein,,mapk1/3,uniprot,q04173,cytoplasm,go:0005637,t202/y204,protein,,,uniprot,,,,positive,d,phosphorylation,t202/y204,cll cells,b-cell,,human,['135'],nan,nan,"whole-cell protein extracts were obtained from cll cells and peripheral blood mononuclear cells from healthy donors and western blot was performed with antibodies against phosphorylated-t202/y204 erk 1/2 and total erk (santa cruz biotechnology, santa cruz, ca, usa) (online supplementary methods).",pmc6395334,1,0.1,39,1,39.1
erk,signalingpathway,,mapk1,uniprot,q05217,cytoplasm,go:0005629,melanocytic neoplasms,disease,,,,,,,positive,d,activated,,,melanocyte,skin,horse,['51'],nan,nan,"constitutive activation of the erk pathway, occurring in the vast majority of melanocytic neoplasms, has a pivotal role in melanoma development. different mechanisms underlie this activation in different tumour settings. the grey phenotype in horses, caused by a 4.6 kb duplication in intron 6 of syntaxin 17 (stx17), is associated with a very high incidence of cutaneous melanoma, but the molecular mechanism behind the melanomagenesis remains unknown. here, we investigated the involvement of the erk pathway in melanoma development in grey horses.",pmc4254013,1,0.1,39,1,39.1
eras,protein,,esr1,uniprot,q92575,cytoplasm,go:0005634,mek/erk,signalingpathway,,,uniprot,"mapk8/9, mapk1/2",cytoplasm,go:0005634,negative,i,inhibition,,,,,,['13'],nan,nan,senescent eras cells fail to induce cytoprotective autophagy upon mek/erk inhibition,pmc5723691,1,0.1,39,1,39.1
dusp6,protein,,dusp6,uniprot,q9y6a8,cytoplasm,go:0005739,mapk pathway,signalingpathway,,,uniprot,mapk,plasma membrane,go:0005886,positive,d,phosphorylation,,,b-cell,,vein,['39'],nan,nan,"we hypothesized that dusp5 and dusp6 may be biomarkers of the mapk output in ptcs, in the context of a negative feedback loop. alternatively, they could act as tumor suppressor genes. for that purpose, we studied the mapk pathway activation, the expression and regulation of dusp5 and dusp6, and the consequences of their inactivation in thyroid cancer cell lines. we found out that dusp5 and dusp6 are overexpressed in human thyroid carcinomas and are surrogate markers of mapk pathway activation. silencing of dusp5 or dusp6, or both phosphatases in thyroid cell lines does not affect proliferation, possibly explained by compensation between phosphatases of the dusp family. finally, dusp5 and dusp6 silencing reduced the cell migration and invasion capacities of two brafv600e thyroid cancer cell lines, thus suggesting a pro-tumorigenic role of these phosphatases in ptc.",pmc5599027,1,0.1,39,1,39.1
dusp5,protein,,dusp5,uniprot,q96775,cytoplasm,go:0005739,bcpap,cell,,,,,cytoplasm,go:0005739,negative,d,binds,,bcpap,epithelial-like,,human,['44'],nan,nan,effects of a third dusp5 sirna on migration and invasion in bcpap and 8505c cells.,pmc5599027,1,0.1,39,1,39.1
dna topoisomerase i (topi),protein,,top1,uniprot,q92059,nucleus,go:0005739,gimatecan,smallmolecule,,,uniprot,,,,negative,d,binds,,,,,,['104'],nan,nan,we investigated antitumor activity and underlying mechanisms of dna topoisomerase i (topi) inhibitor gimatecan and irinotecan in gastric cancer (gc) in vitro cell lines and in vivo patient-derived xenograft (pdx) models.,pmc5729429,1,0.1,39,1,39.1
dermal fibroblasts,cell,,,uniprot,,cytoplasm,go:0005637,nsd1,protein,,nsd1,uniprot,q92538,nucleus,go:0005637,negative,d,expression,,,,,human,['128'],nan,nan,"[27] and dermal fibroblasts have successfully been used to elucidate molecular mechanisms underlying growth disorders [28]–[31]. furthermore, in marked contrast to growth plate chondrocytes they are easily available for analysis. additionally, to our knowledge there are no existing humane chondrocyte cell lines derived from growth plate chondrocytes yet available. we therefore believe that dermal fibroblasts are suited for studying the molecular mechanisms underlying the overgrowth in sos. because 8 of 9 sotos syndrome patients harboured a single nucleotide mutation which did not affect mrna stability (table s1), altered expression of nsd1 was not detected in the array experiments.",pmc3498325,1,0.1,39,1,39.1
gimatecan,drug,orally bioavailable,,uniprot,,,,abcg2,protein,efflux pump,abcg2,uniprot,q92767,plasma membrane,go:0005886,positive,d,inhibition,,nci-n87,gastric epithelial,,human,['106'],nan,nan,"as the third orally bioavailable cpt analogue, gimatecan induced proliferative inhibition and apoptosis promotion in gc cells at a lower concentration, which was consistent with previous studies [13–18]. in 2007, marchetti et al. reported that the abcg2 expression resulted in eight to tenfold resistance to gimatecan, which could be reversed by the abcg2 or mdr1 inhibitors [32]. in this study, we detected the expression of abcg2 and mdr1 in four gc cell lines and observed higher expression of abcg2 and mdr1 in nci-n87 cell line, which might be the reason why gimatecan was relatively insensitive to nci-n87 cells. moreover, it was well known that most chemotherapeutics had effect on normal cells, therefore, our result also suggested that gimatecan could lead to weak growth inhibition in normal immortalized gastric epithelial cell line (data not shown). but even so, the inhibitory activity of gimatecan was still a promising strategy in the treatment of agc.",pmc5729429,1,0.1,39,1,39.1
da-raf1,protein,,,uniprot,unknown,unknown,unknown,myod,protein,,,uniprot,p00386,nucleus,go:0005737,positive,d,induction,unknown,c2c12,skeletal muscle,muscle,mouse,['68'],nan,nan,"the ras–erk pathway negatively regulates skeletal muscle cell differentiation by suppressing the expression or functions of the muscle-specific transcription factors myod and mef2 (lassar et al., 1989; winter and arnold, 2000; perry et al., 2001; tortorella et al., 2001). this suppression results in the aborted expression of myogenin, which induces muscle differentiation. thus, to assess the involvement of da-raf1 in the regulation of skeletal muscle cell differentiation, we first analyzed the expression of daraf1 during the differentiation of c2c12 skeletal muscle cells by quantitative rt-pcr and immunoblotting. undifferentiated myoblasts terminally differentiate to form multinucleated myotubes by cell fusion by shift from the mitogen-rich growth medium containing 10% fbs to the mitogen-poor differentiation medium containing 5% horse serum. well-differentiated myotubes are developed by 96 h under this culture condition. daraf1 mrna was present at a low level in myoblasts but was markedly induced about 10-fold during differentiation (fig. 5, a and b). myog mrna was almost absent in myoblasts but highly induced during differentiation in accordance with the daraf1 expression (fig. 5, a and b). immunoblotting showed that da-raf1 was almost absent in myoblasts but prominently induced during differentiation (fig. 5, c and d). similarly, myogenin and late muscle-specific proteins, myosin heavy chain (myhc) and troponin t (tnt), were also induced (fig. 5, c and d). although the band derived from daraf2 mrna was detected by rt-pcr, da-raf2 protein was hardly detected by immunoblotting even in differentiated c2c12 cells, which is different from in the brain. the increased rate of da-raf1 protein during differentiation was much higher than that of daraf1 mrna. in contrast, the amounts of raf-1, b-raf, and a-raf were almost constant during differentiation (fig. 5, c and d). these results suggest the possibility that da-raf1 positively regulates skeletal muscle cell differentiation.",pmc2064279,1,0.1,39,1,39.1
da-raf,protein,,da raf,uniprot,q92579,cytoplasm,go:0005734,c2c12 cells,cell,,,,,,,negative,d,knockdown,,c2c12,muscle-like,,mouse,['70'],nan,nan,"suppression of the myogenic differentiation phenotype in c2c12 cells by knockdown of endogenous da-raf. (a) knockdown of endogenous da-raf by mouse-specific sirnas but not by rat-specific sirnas in c2c12 cells. the mouse-specific daraf sirnas (m1 and m2) and the rat-specific sirnas (r1 and r2) were expressed in c2c12 cells by the retroviral vector. the amounts of endogenous da-raf1 were analyzed by immunoblotting with the anti–da-raf pab. β-tubulin is shown as a standard. (b) prevention of the cell cycle arrest by rnai of daraf1/2 in c2c12 cells under the differentiation condition. c2c12 cells were transfected with the empty psilencer vector (control) or the sirna-expressing psilencer vectors together with pegfp vector, cultured in the differentiation medium for 48 h, and incubated with brdu for 8 h. egfp fluorescence (green) monitoring the sirna expression is merged with anti-brdu staining (red). the cells expressing m1 or m2 incorporated brdu in the nuclei, but those expressing r1 or r2 did not. (c) ratio of the brdu-incorporating c2c12 cells in the analysis of b. (d) inhibition of myogenin expression and myotube formation by rnai of daraf1/2 in c2c12 cells. egfp fluorescence (green) monitoring the sirna expression is merged with antimyogenin staining (red). the cells expressing m1 or m2 were prevented from differentiation, but those expressing the rat-specific sirnas (r1 and r2) were not. (e) ratio of the myogenin-expressing cells in the analysis of d. (f) the number of nuclei in a c2c12 cell at 72 and 96 h in the differentiation medium in the analysis of d. the values in the graphs are means ± sd (error bars) of three independent experiments. *, p < 0.05; **, p < 0.01 by t test compared with the control at each time point. bars, 20 μm.",pmc2064279,1,0.1,39,1,39.1
crebbp,protein,,crebbp,uniprot,p00842,nucleus,go:0005739,camp-dependent receptor,protein,,,uniprot,,plasma membrane,go:0005886,negative,d,knockdown,,hhd primagraft all cells,b-cell,,human,['36'],nan,nan,"crebbp knockdown in hhd primagraft all cells does not significantly impair the induced expression of camp-dependent or glucocorticoid receptor (gr) target genes and does not impact on glucocorticoid (gc) sensitivity. representative western blot of crebbp (a) and ach3k18 (b) in sicbp and control treated hhd primagraft all cells 24 hours post transplantation, with α-tubulin used as loading control. (c) histograms of rq-pcr data showing mean and sd of the fold change relative to cv in camp responsive genes in sicbp and control treated hhd primagraft all cells, following 90-minute dosing with cv or ibmx/forskolin (i&f) treatment. tbp was used as reference gene. histograms show means of triplicate wells±sd for l779 and l829r and triplicate primagraft samples for l914 (n=3). (d) histograms of rq-pcr data showing mean and sd of the fold upregulation of gr target genes relative to cv in sicbp and control treated hhd primagraft all cells following 24 hours exposure to 1 μm dexamethasone. histograms show intra-assay for mean±sd l779 and l829r and inter-assay for l914 (n=3). (e) viability curves of sicbp and control treated hhd primagraft all cells after dosing with dexamethasone. values plotted represent the mean % viability±sd of triplicate wells for l779 and l829r and triplicate experiments for l914.",pmc5395114,1,0.1,39,1,39.1
cell lytic buffer,buffer,,,,,,,complete protease inhibitor cocktail,proteinmixture,,,uniprot,p00077,cytosol,go:0005739,negative,d,binds,,,,,,['17'],nan,nan,"vehicle‐ or compound‐treated cells were lysed 48 h after drug incubation with cell lytic buffer (sigma; 150 mm nacl, 0.41% bicine, 2% edta) supplemented with complete protease inhibitor cocktail (roche, basel, switzerland) and phosphatase inhibitor cocktail (roche). protein concentration was quantified with bca assay, and normalized samples were resolved with bio‐rad sds/page system on 8–12% protein gels. signal detection was performed with chemiluminescence detection system (ge healthcare, chicago, il, usa).",pmc5537703,1,0.1,39,1,39.1
cd40,protein,receptor,cd40,uniprot,p00627,plasma membrane,go:0005886,b cells,cell,,bcel,uniprot,,,,positive,d,binding,surface,,b-cell,,human,['23'],nan,nan,"regulation of ubiquitin gene expression profile upon belinostat treatment is associated with suppression of sos/mapk and could be rescued by bortezomib treatment. (a) calu‐1 cells were treated with vehicle or belinostat (pxd101) (1 μm). total mrna transcript levels of 84 key ubiquitination genes were assessed with rt2 profiler pcr array. data were presented as bar chart representing the relative value of the significantly altered genes (> twofolds) as compared to vehicle (n = 1). (b) the significantly altered genes identified from rt2 profiler were verified with real‐time quantitative pcr (qpcr) in calu‐1 and h520 cells treated with vehicle or belinostat (pxd101) (1 μm). data were represented as average relative quantification ± sd (n = 3). (c) the genes regulated in the similar manner identified from qpcr were verified with immunoblotting in calu‐1, h520, and h226 cells after treatment with vehicle or belinostat (1 μm). (d) immunoblotting was performed to evaluate the effects of bortezomib (3 μm) on sos2 and p‐erk1/2 in belinostat‐treated cells. (e) immunoblots show the effects of scrambled (scr), fbxo3, or fbxw10 sirna knockdown on affecting the modulation of belinostat on sos/mapk in calu‐1 cells. (f) knockdown efficiency of fbxo3 in calu‐1 cells was confirmed with rt‐qpcr (n = 2). fifty nanomolar sirna was used per transfection. β‐actin shown as loading control.",pmc5537703,1,0.1,39,1,39.1
cd40,protein,,cd40,uniprot,q92573,plasma membrane,go:0005886,cd154 (cd40l),protein,,cd154,uniprot,q96486,plasma membrane,go:0005886,positive,d,binds,,,t cell,,human,['80'],nan,nan,"in the present study, we found that page4 worked exactly in this protective way in pca cells under oxidative stress status. firstly, ros induced page4 expression, which in turn protected cells from apoptosis and dna damage in vitro and promoted tumor growth in vivo. however, when we checked the expression of several tumor less aggressiveness-related genes, such as acta2 [53], fbln1 [54], f2r [55], we found that the expressions of these genes were increased upon overexpression of page4. in addition, rna sequencing data confirmed that a panel of metastasis-related genes were attenuated in page4 overexpressing cells. in support, higher expression of page4 predicted a better dfs of pca in tcga dataset, adhering to its inhibitory role of tumor aggressiveness. this is consistent with our previous finding that page4 mrna level was among markers correlated with a good prognosis of pca [14]. additionally, the previous finding that page4 protein was detected more often in localized pca than metastatic cancer highlights again the reverse correlation between page4 expression and cancer aggressive phenotype [10]. intriguingly, a recent elegant study links page4 to the dynamic androgen-dependence and speculates that page4 interacts with particular kinase suppresses ar hyperactivity and therefore makes cells sensitive to androgen deprivation (adt) treatment [13], which may certainly lead to longer dfs. however, given that many metastatic pca that are lack of page4 expression are sensitive to adt initially, it still could not be excluded that page4 impacts cancer aggressiveness beyond adt sensitivity. thus, it is possible that page4 blocks the development of aggressive pca through attenuating the cell damage caused by oxidative stress which exists in the tumor microenvironment. to this rate, page4 expression in pca cells is potentially to be a predictive biomarker for good cancer prognosis, although it might promote tumor growth in primary site.",pmc6339303,1,0.1,39,1,39.1
c-jun n-terminal kinase (jnk),protein,,jnk,uniprot,q92577,cytosol,go:0005632,ptpn1,protein,phosphatase,ptpn1,uniprot,q92577,cytosol,go:0005632,negative,d,dephosphorylation,jnk,hela,epithelial-like,skin,human,['48'],nan,nan,"the mitogen activated protein kinase (mapk) signaling cascades transmit extracellular stimulations to generate various cellular responses via the sequential and reversible phosphorylation of kinases. since the strength and duration of kinase phosphorylation within the pathway determine the cellular response, both kinases and phosphatases play an essential role in the precise control of mapk pathway activation and attenuation. thus, the identification of pathway-specific phosphatases is critical for understanding the functional mechanisms by which the mapk pathway is regulated. to identify phosphatases specific to the c-jun n-terminal kinase (jnk) mapk pathway, a synthetic screening approach was utilized in which phosphatases were individually tethered to the jnk pathway specific-jip1 scaffold protein. of 77 mammalian phosphatases tested, ptpn1 led to the inhibition of jnk pathway activation. further analyses revealed that of three pathway member kinases, ptpn1 directly dephosphorylates jnk, the terminal kinase of the pathway, and negatively regulates the jnk mapk pathway. specifically, ptpn1 appears to regulate the overall signaling magnitude, rather than the adaptation timing, suggesting that ptpn1 might be involved in the control and maintenance of signaling noise. finally, the negative regulation of the jnk mapk pathway by ptpn1 was found to reduce the tumor necrosis factor α (tnfα)-dependent cell death response.",pmc5636874,1,0.1,39,1,39.1
breast cancer,disease,,,uniprot,,,,benign breast disease,disease,,,uniprot,,,,negative,d,none,,,,,human,['171'],nan,nan,"the study population consisted of 300 breast cancer cases and 300 benign breast disease controls who were treated at tri-service general hospital (tsgh) between 1992.06 and 2007.12. the recruited benign breast diseases comprised 237 nonproliferative lesions (np, 124 fibroadenoma, 107 fibrocystic changes, 6 adenosis) and 63 proliferative diseases without atypia (pdwa, 44 mild ductal hyperplasia and 19 sclerosing adenosis), which have a lower relative risk of breast cancer [46]. the breast cancer cases were comprised of 61 ductal carcinoma in situ, 27 infiltrating ductal carcinoma (idc) grade i (gi), 110 idc gii, 74 idc giii, 18 infiltrating lobular carcinoma (ilc), 7 colloid carcinoma, and 3 medullary carcinoma. in accordance with the tsgh institutional review board guidelines (tsgh-irb-093-05-00004, 097-05-008, 098-05-204, 098-05-311, 099-05-273, and 100-05-236), patients were followed for at least eight years postoperative follow-up. clinical information was obtained from patient charts and pathological reports. tumor staging and pathological grading were recorded according to the american joint committee on cancer (ajcc) 7th tumor-node-metastasis (tnm) staging system and the modified bloom-richardson histologic grading criteria, respectively.",pmc5410235,1,0.1,39,1,39.1
belinostat,drug,small molecule,,uniprot,,,,ubiquitin-related proteins,protein,,,uniprot,,,,positive,d,degradation,,,,,human,['25'],nan,nan,"in summary, we have described a novel mechanism of belinostat sensitivity against lung scc, a disease in which small‐molecule inhibitors have mostly failed due to the lack of actionable driver oncogenes. this mechanism involves the disturbance of the expressions of ubiquitin‐related proteins, which influences the activity of key survival signals, leading to an increase in cellular apoptosis. in the context of scc, belinostat treatment triggers the proteasomal degradation of sos proteins and downregulates the downstream mapk signaling. interestingly, hdac inhibitors have been previously implicated in the depletion of mutant p53 through the transcriptional induction of mdm2, an e3 ubiquitin ligase that negatively regulates p53, instead of directly affecting tp53 transcription (blagosklonny et al., 2005). likewise, a similar finding was earlier reported whereby a tyrosine kinase inhibitor, ci‐1033, significantly enhanced ubiquitination in her2 molecule together with the inhibition of kinase activity (citri et al., 2002). these reports, along with our own experimental findings discussed in this manuscript, highlight the use of compounds that enhance drug‐induced ubiquitin modification to augment antineoplastic effects and warrant the use of these inhibitors in further studies. nevertheless, the lack of efficacy in preclinical xenograft models suggests that additional work is needed for clinical development of belinostat in scc tumors.",pmc5537703,1,0.1,39,1,39.1
belinostat,drug,,,uniprot,,,,sos/mapk signaling,signalingpathway,,,uniprot,,,,negative,d,inhibition,,calu-1,epithelial-like,lung,human,['22'],nan,nan,"we verified the clusters of gene panels derived from the microarray using rt2 profiler pcr array specifically targeting the expression of well‐established ubiquitination‐related genes encoding for e1, e2, and e3 enzymes. the gene expression changes were measured in calu‐1 cells 24 h after belinostat treatment, when the inhibition of sos/mapk signaling was first observed (fig. 4). the significantly altered genes were identified from the array (fig. 6a) and validated by qpcr in both calu‐1 and h520 cells (fig. 6b). among these genes, fbxo3, fbxw10, and ube2c were identified as commonly altered genes (fig. 6b). moreover, exposure to 1 μm belinostat increased protein expressions of fbxo3 and fbxw10, but decreased ube2c, in both calu‐1 and h520 cells, providing concordance to the rt2 gene expression profile (fig. 6c). similar observations were made in belinostat‐resistant h226 cells (fig. 6c). taken together, the observations suggest a significant mechanism of functional protein regulation that occurs through epigenetic modulation of ubiquitin‐proteasome pathways by belinostat treatment. moreover, these results may explain the downregulation of mapk signaling through ubiquitination and degradation of sos proteins.",pmc5537703,1,0.1,39,1,39.1
bcl2/bclxl,protein,,bcl2l1,uniprot,q07817,mitochondria,go:0005739,ras mutant crc organoids,other,,,fplx,ras mutant crc organoids,,,negative,d,inhibition,,,,,human,['86'],nan,nan,"here, we explored the use of navitoclax, a clinically tested bcl2/bclxl inhibitor, in targeted therapies against ras mutant crc organoids. indeed, straightforward atp-based screening confirmed that navitoclax, when combined with afatinib (figure 9a, left panel), selumetinib (figure 9a, middle panel), or both (figure 9a, right panel) is far more efficient in antagonizing tumor organoid growth than any of the related monotherapies. importantly, regarding the dose-limiting effects of navitoclax, we show that robust dual inhibition of the egfr-ras-erk pathway (1 µm afatinib/1 µm selumetinib) is exceptionally potent in sensitizing navitoclax-induced effects (figure 9a, right panel). such strong sensitization could not be achieved by afatinib (1 µm) alone or selumetinib (1 µm) alone. similar results were obtained in other patient-derived crc organoids that harbor a kras mutation (figure 9—figure supplement 1) or, alternatively, with different combinations of inhibitors targeting the egfr-ras-erk pathway (figure 9—figure supplement 2).",pmc5127645,1,0.1,39,1,39.1
bcl-xl,protein,,bcl2l1,uniprot,q07817,mitochondria,go:0005739,8505c cells,cellline,,,,,,,negative,d,binds,,30.103 bcpap cells,epithelial-like,,human,['40'],nan,nan,"the anchorage-independent growth was analyzed through a soft agar colony formation assay. twenty four hours after transfection with sirna, cells (25.103 8505c cells or 30.103 bcpap cells) were seeded on 6-well plates in 0.3% agar in culture medium over a base layer of 0.7% agar, colonies were microscopically counted after 3 weeks of culture.",pmc5599027,1,0.1,39,1,39.1
ascites,other,,,uniprot,,,,animal abdomen,organ,,,uniprot,,,,negative,d,binds,,,,,animal,['172'],nan,nan,animal abdomen appears dark-gray/green or ascites exceed 20% of the animal weight.,pmc5410235,1,0.1,39,1,39.1
gfap,protein,,gfap,uniprot,q01502,cytoplasm,go:0005637,iba1,protein,,iba1,uniprot,q92678,cytoplasm,go:0005637,positive,d,immunoprecipitation,,,microglia,spinal cord,rat,['153'],nan,nan,"elevated gfap expression was also verified using the western blot analysis 1, 4,",pmc6113736,1,0.1,39,1,39.1
yeast,organism,,ymr194c,uniprot,q92974,cytoplasm,go:0005632,cryptic variants,geneticvariant,,,fplx,cryptic variants,nucleus,go:0005632,positive,d,genetic-interaction,,,,,yeast,['146'],nan,nan,"some genetic polymorphisms have phenotypic effects that are masked under most conditions, but can be revealed by mutations or environmental change. the genetic and molecular mechanisms that suppress and uncover these cryptic genetic variants are important to understand. here, we show that a single mutation in a yeast cross causes a major phenotypic change through its genetic interactions with two specific combinations of cryptic variants in six genes. this result suggests that in some cases cryptic variants themselves play roles in revealing their own phenotypic effects through their genetic interactions with each other and the mutations that reveal them. we also demonstrate that most of the genes harboring cryptic variation in our system are transcription factors, a finding that supports an important role for perturbation of gene regulatory networks in the uncovering of cryptic variation. as a final part of our study, we interrogate how a mutation exposes combinations of cryptic variants and obtain evidence that it does so by disrupting the silencing of one or more genes that must be expressed for the cryptic variants to exert their effects. to prove this point, we delete the transcriptional repressor that mediates this silencing and demonstrate that this deletion reveals a similar set of cryptic variants to the ones that were discovered in the initial mutant background. these findings advance our understanding of the genetic and molecular mechanisms that reveal cryptic variation.",pmc4618523,1,0.1,39,1,39.1
microglia,cell,,mgc83,uniprot,q92577,brain,go:0005634,pro-inflammatory cytokines,protein,,cytokine,uniprot,cytokine,blood,go:0005634,positive,i,activation,,,b-cell,brain,mouse,['147'],nan,nan,"in recent years, substantial evidence has shown that the injury-induced inflammation",pmc6113736,1,0.1,39,1,39.1
mir-320,smallrna,microrna,mir320a,mirbase,mi0000032,cytoplasm,go:0005739,cdk6,protein,cyclin-dependent kinase,cdk6,uniprot,q05240,cytoplasm,go:0005739,negative,d,binds,,glioma,tumor,brain,human,['181'],nan,nan,mir-320 suppressed glioma cells proliferation through inducing cell cycle arrest at g0/g1 phase,pmc5609034,1,0.1,39,1,39.1
mir-320,smallmolecule,microrna,mir320a,mirbase,mir320a,cytoplasm,go:0005739,u87,cellline,glioma,,,,cytoplasm,go:0005739,positive,d,binds,,u87,glioma,,human,['182'],nan,nan,"to investigate the biological function of mir-320 in glioma cells, exogenous mir-320 expression by mimic transfection was performed initially. transfection of mimics significantly suppressed cell proliferation rates and colony formation abilities in both glioma cell lines, u87 and u251 (fig. 3a–c). we then explored the effect of mir-320 expression on cell cycle progression by flow cytometry methods. compared to the cells transfected with control mimics, glioma cells with mir-320 transfection showed redistributed cell cycle progression with an increased proportion of cells in g0/g1 arrest (fig. 3d, e).",pmc5609034,1,0.1,39,1,39.1
mir-320,noncodingrna,microrna,mir320a,mirbase,mir320a,cytoplasm,go:0005739,glioma cells,cell,,,uniprot,none,cytoplasm,go:0005739,positive,d,binds,,glioma cells,tumor,none,human,['183'],nan,nan,"the effect of mir-320 mimics on gliomas cell apoptosis was examined using annexin v and pi double staining assay and western blotting analysis of the caspase-3 protein. cells were harvested at 48 h after transfection and apoptosis was assessed by fcm. compared with the control group, the proportion of apoptotic cells in the mir-320 mimic-transfected group was significantly higher (fig. 4a, b). in addition, mir-320 transfection resulted in caspase-3 activation evidenced by the increased protein level of cleaved caspase-3 (fig. 4c), suggesting mir-320 mediated glioma cell apoptosis is caspase enzyme dependent.",pmc5609034,1,0.1,39,1,39.1
mir-320,mirna,,mir320a,mirbase,mir320a,cytoplasm,go:0005735,pbx3,protein,,pbx3,uniprot,q96568,nucleus,go:0005634,negative,d,binds,3' utr,glioma,glioma,brain,human,['177'],nan,nan,"mir-320 downregulation and pbx3 upregulation was found in glioma tissues. luciferase reporter assays identified mir-320 directly blinds to the 3′ utr of pbx3 in glioma cells. mir-320 mimic transfection suppressed glioma cells proliferation, and induced cell cycle arrest and apoptosis. both mir-320 overexpression and pbx3 knockdown inhibited raf-1/mapk activation.",pmc5609034,1,0.1,39,1,39.1
mir-320,microrna,,mir320a,uniprot,q06265,cytoplasm,go:0005634,pbx3,protein,,pbx3,uniprot,q92578,cytoplasm,go:0005634,negative,d,binds,3' utr of pbx3 mrna,glioma,glioma,brain,human,['180'],nan,nan,"mir-320 expression was down-regulated, while pbx3 was up-regulated in glioma tissues",pmc5609034,1,0.1,39,1,39.1
mir-181a,microrna,,mir181a,mirbase,mir-181a,cytoplasm,go:0005739,aml cells,cells,,,uniprot,aml,cytoplasm,go:0005739,negative,d,binds,,,,,murine,['56'],nan,nan,higher levels of mir-181a are associated with a less aggressive phenotype in aml cells and longer survival in a murine aml model,pmc5312311,1,0.1,39,1,39.1
micrornas (mirnas),rna,endogenous,mirn320,uniprot,q07817,cytoplasm,go:0005739,target mrna transcripts,protein,,,fplx,tcr,plasma membrane,go:0005886,negative,d,binds,,,b-cell,,human,['178'],nan,nan,"micrornas (mirnas) are a class of short, endogenous, non-coding rna molecules that function as post-transcriptional gene regulators through binding to complementary sequences in the 3′utrs of target mrna transcripts [4, 5]. growing evidence has shown that aberrant expression of mirnas are involved in the progression and development of human cancers, either as oncogenes or tumor suppressors [6, 7]. previous investigations have indicated that mir-320 is involved in the development of several human tumors [8–12]. dong et al. found mir-320 showed significantly low expression in glioblastoma patients [13], however, the exact role of mir-320 in glioma occurrence and development remains unknown.",pmc5609034,1,0.1,39,1,39.1
glial fibrillary acidic protein (gfap),protein,,gfap,uniprot,p01730,cytoplasm,go:0005886,neuronal pentraxin (nptx2),protein,,nptx2,uniprot,o14727,cytoplasm,go:0005886,positive,d,co-localization,,,neuron,brain,human,['151'],nan,nan,"proteintech (wuhan, china). glial fibrillary acidic protein (gfap) and neuronal",pmc6113736,1,0.1,39,1,39.1
mir-382-5p,smallrna,mirna,mir382h5,mirbase,mir382h5,cytoplasm,go:0005739,cell viability,cellularprocess,,,uniprot,q07817,mitochondria,go:0005739,positive,d,binds,,mcf-7,adenocarcinoma,breast,human,['167'],nan,nan,"to evaluate the biological effects of mir-382-5p, we performed gain-of-function and loss-of-function studies in mcf-7 cells (lower endogenous mir-382-5p) and hs578t cells (higher endogenous mir-382-5p, figure 1a). mtt assays and soft-agar colony-formation assays were used to compare the effects of mir-382-5p on cell viability and clonogenicity. mcf-7 cells transfected with mir-382-5p mimics revealed a dose-dependent induction of cell viability than non-treated controls (ntc) or mirna mimic negative controls (mnc) groups (figure 2a). similarly, mir-382-5p dose-dependently induced a higher colony-forming ability than ntc or mnc groups (figure 2b). conversely, hs578t cells transfected with mir-382-5p inhibitors attenuated endogenous mir-382-5p and dose-dependently decreased cell viability (figure 2a) and colony-forming ability (figure 2b) than ntc or mirna inhibitor negative control (inc) groups. these data suggest that mir-382-5p enhanced cell viability and may induce higher tumorigenicity, at least in an experimental cell model.",pmc5410235,1,0.1,39,1,39.1
mirna,other,,,uniprot,,cytoplasm,go:0005632,rerg,protein,,rerg,uniprot,q9h2a9,cytoplasm,go:0005632,negative,d,binds,,"mcf-7, hs578t","adenocarcinoma, carcinoma","breast, lung",human,['170'],nan,nan,"a. mcf-7 cells were transiently co-transfected with four combinations for 72 h: 120 pmol mirna mimics negative control and 2 μg pcdna3.1 empty vector (mnc+vec), 120 pmol mir-382-5p mimics and 2 μg pcdna3.1 empty vector (m382+vec), 120 pmol mirna mimics negative control and 2 μg pcdna3-rerg (mnc+rerg), and 120 pmol mir-382-5p mimics and 2 μg pcdna3-rerg (m382+rerg). the inductive effects of mir-382-5p on (a) cell viability, b. clonogenicity, c. migration and invasion were impaired in mcf-7 cells co-transfected with m382+rerg. the growth curves and bar-charts were used to show the relative levels which were normalized to the mnc+vec groups (a&b: * p < 0.05, ** p < 0.01, *** p < 0.001; and c: ** p < 0.01, *** p < 0.001 for migration, ### p <0.001 for invasion, student t-test). hs578t cells were also transiently transfected with other four combinations for 72h: 120 pmol mirna inhibitors negative control and 2 μg pcdna3.1 empty vector (inc+vec), 120 pmol mir-382-5p inhibitors and 2 μg pcdna3.1 empty vector (i382+vec), 120 pmol mirna inhibitors negative control and 2 μg pcdna3-rerg (inc+rerg), and 120 pmol mir-382-5p inhibitors and 2 μg pcdna3-rerg (i382+rerg). hs578t co-transfected with i382+rerg additively reduced (a) cell viability, (b) clonogenicity, (c) migration and invasion. the growth curves and bar-charts were used to show the relative levels which were normalized to the inc+vec groups (a&b: *** p < 0.001, and c: *** p < 0.001 for migration, ### p <0.001 for invasion, student t-test). d. the protein levels of the ras/erk signaling members were determined using western blotting. and mcf-7 cells co-transfected with m382+rerg attenuated mir-382-5p induced ras/erk signaling effectors, pmek1/2 and perk1/2. otherwise, hs578t cells co-transfected with i382+rerg rescued rerg expression and additively deactivated praf1, pmek1/2, and perk1/2. the bar-charts were used to show the relative protein levels which were normalized to gapdh and the mnc+vec or inc+vec groups were used as the comparative baseline in mcf-7 and hs578t cells, respectively (* p < 0.05, ** p < 0.01, *** p < 0.001, student t-test).",pmc5410235,1,0.1,39,1,39.1
mapk/erk,signalingpathway,,,uniprot,,plasma membrane,go:0005886,sos,protein,,,uniprot,,plasma membrane,go:0005886,negative,d,activates,,,,,,['131'],nan,nan,"in conclusion, for the first time sos is shown to be associated with deregulation of the mapk/erk pathway. an altered activity of this pathway may be an important contributor to the longitudinal overgrowth.",pmc3498325,1,0.1,39,1,39.1
map4k4,protein,serine/threonine kinase,map4k4,uniprot,q9h2d7,cytoplasm,go:0005739,mapk/erk signaling,signalingpathway,,,uniprot,mapk/erk signaling,cytoplasm,go:0005739,positive,d,activates,,,epithelial-like,lung,human,['138'],nan,nan,"the serine/threonine kinase map4k4 is a member of the ste20p (sterile 20 protein) family. map4ks were discovered in 1995 as a key kinase in the mating pathway in saccharomyces cerevisiae (wu et al., 1995). map4k4 is best known as an inflammation‐related kinase: map4k4 promotes vascular inflammation (roth flach et al., 2015) and sirna targeting macrophage map4k4 suppresses systemic inflammation (aouadi et al., 2009). although emerging evidence suggests that map4k4 is involved in many aspects of cell functions and processes, information regarding map4k4 in different types of cancer is very limited. results from one previous study showed that map4k4 protein level was elevated in lung adenocarcinoma and its elevation was negatively associated with patients’ prognosis (qiu et al., 2012). but except for the correlative observations, whether and how map4k4 contributes to lung adenocarcinoma remain to be determined. the current study has identified map4k4 as a novel activator of mapk/erk signaling in lung adenocarcinoma. the results from functional in vitro and in vivo studies showed that map4k4 was required for the maintenance of the malignant phenotype of lung adenocarcinoma. our findings suggest that pharmacological inhibition of map4k4 could be an effective approach to targeting lung adenocarcinoma, as a stand‐alone therapy or in combination with other treatment.",pmc5467491,1,0.1,39,1,39.1
map4k4,protein,,map4k4,uniprot,q9h0d7,plasma membrane,go:0005886,erk pathway,pathway,,,,,,,positive,d,elevation,,,,,human,['143'],nan,nan,"to dramatically change the outlook for patients with lung adenocarcinoma, it is essential to identify target that may be exploitable in relapsed egfr‐mutant tumors as well as in lung adenocarcinomas lacking mutations in druggable targets. to this end, the current study has identified map4k4 as a previously unrealized erk pathway activator and it is required for the maintenance of malignant phenotype of lung adenocarcinoma in vitro and in vivo. our results indicate that map4k4 elevation in lung adenocarcinoma is independent of somatic mutations of kras or egfr. importantly, we find that map4k4 regulation of mapk/erk pathway is also independent of kras or egfr mutation status, suggesting that map4k4‐targeted therapy could be an effective treatment for a broad range of patients with lung adenocarcinoma.",pmc5467491,1,0.1,39,1,39.1
map4k4,protein,,map4k4,uniprot,q96739,plasma membrane,go:0005886,h1975,cellline,,,uniprot,,,,negative,d,knockdown,,h1975,b-cell,,mouse,['140'],nan,nan,"all animal procedures were carried out according to the protocols approved by the institutional animal care and use committee at the university of pittsburgh. four‐ to five‐week‐old nude mice (charles river) housed in a sterile environment were used for the experiments. for xenograft experiments, 1× 106 h1975 shrna control cells or map4k4‐knockdown cells were subcutaneously injected into the left or right flanks of the mice, respectively. eight mice were used. tumor size was determined by caliper measurements twice a week. tumor volume was calculated using the formula: v = ½ × a × b",pmc5467491,1,0.1,39,1,39.1
lovastatin,drug,,hgnc:302,uniprot,qrl229,plasma membrane,go:0005886,erk1/2,protein,,hgnc:303,uniprot,p00443,plasma membrane,go:0005886,negative,d,inhibition,,,neuronal,brain,mouse,['164'],nan,nan,"in addition to d1r-pathway, the erk1/2 cascade can also be activated by the nmda receptor via ras21,22. in this pathway, lovastatin, a drug widely used to treat hyperlipidemia and able to reduce ras activity by inhibiting its isoprenylation, significantly attenuates the phosphorylation of erk1/2 and the development of lid23,24. in addition, genetic inactivation of the ras-guanine nucleotide-releasing factor 1 (ras-grf1), a neuronal specific activator of ras, attenuates dyskinesia in mice and non-human primates3,5.",pmc6194127,1,0.1,39,1,39.1
kras,gene,oncogene,hras,ensembl,enst00000376757,nucleus,go:0005739,kras mutations,geneticalteration,missense mutation,,uniprot,q07817,cytoplasm,go:0005739,positive,d,expression,nucleus,,,,human,['63'],nan,nan,"using data from tcga, we have confirmed and extended the early observation that kras gene expression in samples harboring kras mutations is elevated relative to their wt kras counterparts in many, but not all tumor types. notably, the increase is significant in the principal tumor types where kras mutation is thought to have a driver role (luad, paad, and coad) (figure 1a). we extended this to show that the same principle applies to the 2 other ras genes and that it also applies to the 2 major spliced isoforms of kras, kras4a, and kras4b (figure 1b and c). we also demonstrated that the mutation-associated expression increase could be reproduced in cell lines (figure 3), providing a convenient experimental paradigm for further experiments.",pmc5467702,1,0.1,39,1,39.1
hras,protein,oncogene,hras,uniprot,q05605,cytoplasm,go:0005636,tumor,disease,,,uniprot,tumor,cytoplasm,go:0005636,positive,d,mutation,,,epithelial-like,,human,['60'],nan,nan,"for hras, there are a total of 7 tumor types that meet these criteria—bladder (blca), head and neck squamous cell (hnsc), pheochromocytoma and paraganglioma (pcpg), lung squamous cell (lusc), skcm, thymoma (thym), and thca. of these, we observed a statistically significant increase in hras in blca, hnsc, and pcpg tumors with hras mutations (figure 2a). in skcm, thym, and thca (figure 2a), the trend was apparent, but the number of samples was too low for significance (values indicated on figure). as with the exceptions noted for kras, there was no evidence of the trend in lusc (data not shown).",pmc5467702,1,0.1,39,1,39.1
mitf,protein,,pparg,uniprot,p02358,cytoplasm,go:0005637,stx17,protein,,stx17,uniprot,q92677,cytoplasm,go:0005637,positive,d,binds,,,melanocyte,skin,zebrafish,['53'],nan,nan,"we have previously demonstrated that the causative mutation for the grey horse phenotype encompassing the dramatically increased risk of melanoma development is a 4.6 kb duplication in intron 6 of syntaxin 17 (stx17) ([17]; referred to as grey mutation thereafter). this dominant mutation constitutes a cis-acting regulatory mutation that upregulates the expression of both stx17 and the neighboring gene nr4a3 encoding nuclear receptor subfamily 4, group a, member 3. it is still an open question if upregulation of stx17 or nr4a3 expression is crucial, or if both events are required for the phenotypic effects associated with grey phenotypes. we have recently demonstrated that the duplicated region contains a weak melanocyte-specific enhancer that becomes a strong enhancer when duplicated [18]. the tissue specificity is explained by the presence of two perfect binding sites for mitf (microphthalmia-associated transcription factor) within the duplicated sequence. this interpretation is strongly supported by results from transgenic zebrafish where the horse duplicated sequence could drive melanocyte-specific reporter expression and this activity was inhibited by silencing mitf using morpoholinos [18]. furthermore, we have observed a positive correlation between the copy number of the grey mutation and the melanoma progression, suggesting that the mutation might constitute a melanoma-driving element [19]. while the causative genetic link between the grey mutation and development of grey horse melanoma is well established, the molecular mechanism behind this link remains uncharacterized as well as it is not known whether additional somatic mutations are required for tumourigenesis.",pmc4254013,1,0.1,39,1,39.1
hras,protein,,hras,uniprot,q05282,plasma membrane,go:0005886,cd44,protein,,cd44,uniprot,q05283,plasma membrane,go:0005886,negative,d,downregulation,,,none,none,human,['119'],nan,nan,the hras-erk1/2 pathway is inactivated via the α4 integrin chain,pmc5432316,1,0.1,39,1,39.1
hras,protein,,hras,uniprot,q02805,cytosol,go:0005634,α4β1 integrin,protein,,itga4,uniprot,q05577,plasma membrane,go:0005886,positive,d,binding,,hacat,epithelial-like,,mouse,['121'],nan,nan,"to proof the physiological link between cell adhesion via the α4β1 integrin and hras we used hacat cells that endogenously express the α4 integrin chain. we confirmed that the adhesion of hacat cells to the gc1q or the collagen type i ligands was due to the α4β1 or the α2β1 integrins, respectively, by performing cell adhesion in the presence of the specific integrin blocking antibodies. thus, the α4β1 mab greatly reduced cell adhesion to gc1q and the α2β1 mab fully inhibited cell adhesion to collagen type i (figure 2a).",pmc5432316,1,0.1,39,1,39.1
helicobacter pylori,bacterium,,helicobacter pylori,uniprot,a0a1a0a0m0,,,gastric cancer,disease,,,uniprot,gastric cancer,,,positive,d,infects,,,epithelial,stomach,human,['77'],nan,nan,"the latest data from cancer today (part of the globocan project) [1] confirm that gastric cancer is the fifth most common cancer and the third leading cause of cancer-related mortality. incidence rates of gastric cancer vary dramatically according to the region of the world. the age standardized rate (asr) of incidence is 22.4/100,000 in east asia, 11.4/100,000 in eastern europe, and 9.5/100,000 in south america, as compared to less than 5/100,000 in africa, australia, north america, and northern europe. chile has the seventh highest incidence of gastric cancer, with an asr of 17.8/100,000, similar to latin american countries of central america and the pacific coast of south america, such as peru, guatemala, ecuador, and costa rica. risk factors for gastric cancer include high salt intake, low fruit and vegetable consumption, smoking, helicobacter pylori infection, and genetic factors [2]. in 2015, mocellin et al. [3] published the results of a systematic review and meta-analysis of the evidence linking polymorphisms with gastric cancer, and found 11 variants that are significantly associated with a high level of summary evidence. some of the polymorphisms were found in hypothesis-driven studies based on a candidate gene approach. in this study, asian ancestry associated with some polymorphisms, and caucasian ancestry with other polymorphisms.",pmc6356706,1,0.1,39,1,39.1
hdac,enzyme,histone deacetylase,hda1,uniprot,p00162,cytoplasm,go:0005634,belinostat,drug,hdac inhibitor,,uniprot,q9y2s9,,,positive,d,inhibition,,,,,human,['19'],nan,nan,"to determine the sensitivity of hdac inhibitors in scc cells, we screened a panel of 10 lung scc cells and three normal fibroblast cells against belinostat to determine the half‐maximum inhibitory concentrations (ic50). all three lung fibroblast cells were shown to have similar toxicity to belinostat (ic50 ~ 3 μm). in order to avoid normal tissue toxicity, we defined lung scc cells with ic50 < 3 μm as belinostat sensitive, while those above this cutoff as belinostat resistant (fig. 1a). interestingly, lung scc cells (h2066, sw900, h2170, calu‐1, h520, and sk‐mes‐1), which we previously demonstrated to exhibit decreased sensitivity to cisplatin, were highly sensitive to belinostat (kong et al., 2015). the reciprocally inverse sensitivity among belinostat and cisplatin suggested the potential for synergistic combination. our combination index (ci) analysis revealed that belinostat synergized with cisplatin in most cell lines, with the most pronounced synergy observed in sk‐mes‐1, calu‐1, and h520 cells (ci < 0.6) (fig. 1b). however under anchorage‐independent growth, belinostat showed additive effect when used in combination with cisplatin (fig. s1a), with average ci (ed50‐ed80) in between 0.82 and 1.19 (fig. s1b). taken together, these results suggest that belinostat regulates chemosensitivity in lung scc cells, and are consistent with previous reports on hdac inhibitors (ramalingam et al., 2010).",pmc5537703,1,0.1,39,1,39.1
h2b-mneongreen,protein,,h2b,uniprot,q9h2b1,cytoplasm,go:0005739,organoids,other,,,fplx,organoids,plasma membrane,go:0005886,negative,d,bound,,,epithelial-like,,human,['89'],nan,nan,"five days after trypsinization, h2b-mneongreen-expressing organoids were plated in matrigel in glass-bottom 96-well plates and mounted on an inverted confocal laser scanning microscope (leica sp8x) under controlled conditions (37°c, 6% co2). drugs were added to the organoids just prior to imaging. for 72 hr, organoids were imaged every 15 min in xyzt-mode using a 40x objective (1.1na) and a 506 nm laser excitation light from a tunable white light laser for 72 hr. the images were converted using imagej/fiji software into manageable and maximally informative videos, combining z-projection, depth color-coding and merging with transmitted light images (see source code files, ‘organoid movie macro’).",pmc5127645,1,0.1,39,1,39.1
grey horses,organism,,,uniprot,,,,melanoma,other,,,fplx,melanoma,,,negative,d,unknown,,,,,grey horses,['52'],nan,nan,"grey horses exhibit a fascinating pigment cell disorder phenotype manifested by gradual loss of coat pigmentation, vitiligo-like skin depigmentation and a high incidence of melanoma. it is estimated that ~80% of grey horses older than 15 years have melanomas, while this is a rare condition in horses with other coat colors [13]. the primary tumours arise in the dermis of the glabrous skin under the tail, in the perianal and genital regions, lips and eyelids, but could also occur internally [13, 14]. although most of the melanomas have a long initially benign growth period, up to 66% of these tumours may become malignant with metastases formation in other organs [15]. despite the unusual clinical behaviour, the grey horse melanomas (ghm) share common features with certain human cutaneous melanomas and malignant blue nevi, suggesting similarities in pathogenesis [16].",pmc4254013,1,0.1,39,1,39.1
mir-382-5p,mirna,mirna-382,mir382hg,mirbase,mir382hg,cytoplasm,go:0005739,rerg,protein,,rerg,uniprot,q96778,cytoplasm,go:0005739,negative,d,binds,wild-type 3'utr,hs578t,breast cancer,breast,human,['168'],nan,nan,"the predicted mir-382-5p targeting site within the rerg 3′utr is shown in figure 3a. we performed luciferase reporter assays to validate rerg as a direct mir-382-5p target gene. we found that mir-382-5p mimics reduced luciferase activity in cells transfected with p-mir-reporter carrying the wild-type rerg 3′utr compared to mnc-transfected cells. however, there was no change in luciferase activity in cells co-transfected with mir-382-5p mimics or mnc with empty vector alone or p-mir-reporter carrying amutant rerg3′utr (figure 3b). in addition, mir-382-5p mimics had a less repressive effect on hs578t cells in which endogenous mir-382-5p is already higher compared to other breast cancer cell lines (figure 1a).",pmc5410235,1,0.1,39,1,39.1
ras,protein,,ras,uniprot,q92062,cytoplasm,go:0005739,kras,protein,,kras,uniprot,q92063,cytoplasm,go:0005739,positive,d,phosphorylation,,,b-cell,,human,['55'],nan,nan,"ras proto-oncogenes encode small gtpase proteins, that is, kras, nras and hras, that are involved in homeostatic mechanisms of proliferation, differentiation and apoptosis of normal cells [29]. whereas kras and nras are frequently mutated and activated in aml, hras mutations are rare, and hras wild-type expression is the lowest with respect to the other ras isoforms in the hematopoietic system [29]. aberrant activation of ras signal transduction is often found in human neoplasia [30–43]. in hematopoietic malignancies, including aml, activating oncogenic ras mutations contribute to malignant phenotypes by phosphorylating and activating downstream effectors such as the mitogen-activated protein kinase kinase (mapkk, also known as mek), mitogen-activated protein kinase (mapk), and the pi3k-akt downstream effectors, thereby promoting aberrant cell proliferation and survival [29]. however, to date, an effective therapeutic approach targeting ras directly remains to be developed.",pmc5312311,1,10,18,1,28
ras,protein,,ras,uniprot,q92677,plasma membrane,go:0005886,kras,protein,,kras,uniprot,q92677,plasma membrane,go:0005886,positive,d,mutation,,,,,human,['99'],nan,nan,"through an integrated analysis of literature data and internal datasets incorporating both cell line models and human tumors, we identified a ras pathway signature consisting of 147 genes that is coherently expressed across multiple datasets. the ras pathway signature has a high sensitivity for detecting kras mutant cell lines and human tumors, but also identifies samples that have apparent ras pathway activation in the absence of a kras mutation. we show that baseline levels of the ras pathway signature predict resistance to akt inhibition and sensitivity to mek inhibition in cell line panels independent of kras mutation status, that the signature is downregulated by mek inhibition, and that the signature is a better predictor of ras pathway dependence compared to kras mutation status in lung cancer cell lines. in human tumors, the ras signature is coherent across multiple tumor types, is elevated in clinical subtypes not known to harbor kras mutations (i.e. er negative breast cancer), and predicts resistance to cetuximab in metastatic colorectal cancer. these data demonstrate that the ras signature significantly expands the population of human tumors exhibiting ras pathway deregulation, and has potential clinical utility in identifying lung and breast tumors where ras pathway dependence should be considered when choosing appropriate targeted therapies.",pmc2911390,1,10,18,1,28
braf,protein,,braf,uniprot,p00745,cytoplasm,go:0005886,kras,protein,,kras,uniprot,p00747,cytoplasm,go:0005886,positive,d,expression,cytoplasm,,b-cell,,human,['49'],nan,nan,"in order to identify the transcriptional profiles related to braf, nras and kras mutations in primary tumors, we used microarray technology to investigate a large number (n = 142) of the samples analyzed by ngs. assuming that alterations in a limited number of myeloma cells do not appreciably affect gene expression, we arbitrarily chose a lower vaf cut-off value of 20% for the supervised analysis of 60 wild-type and 68 mutated patients. they differentially expressed 86 genes (18 of which emerged at the highest stringency level) (supplementary table 4a): 27 up- and 59 down-regulated in the mutated cases. interestingly, functional enrichment analysis revealed the involvement of a statistically significant fraction of modulated transcripts in mapk signalling (prkd2, spred2, mapkapk2, cd300a, arl6ip5, dusp6, ppm1l, grb2, lamtor3, spred1, lyn, edn1, rasgrp1 and acvr1b) at both biological process (go:0000165, q-value=3.29e-03) and pathway level (198779 wikipathway, q-value=1.33e-02) (supplementary table 4b).",pmc4695180,1,10,11,1,21
"mek1,2",protein,,mapk1,uniprot,p00164,cytoplasm,go:0005739,"erk1,2",protein,,mapk3,uniprot,q05207,cytoplasm,go:0005739,negative,d,inhibition,,eras,fibroblast,,rat,['10'],nan,nan,"here, we have used transformed rat embryo fibroblasts expressing e1aad5 and cha-ras oncogenes (eras cells) as a model to study a role of mek/erk pathway in regulation of autophagy, which is involved in the maintenance of viability and implementation of senescence program. senescence was induced by treatment with hdac inhibitor sodium butyrate (nabut, 4 mm). mek1,2 inhibitor pd0325901 (pd, 1 μm) was used for long-term inhibition of mek/erk pathway. the treatment of eras cells with pd0325901 leads to a complete cessation of erk1,2 phosphoryla-tion that persists for 2-120 h as evidenced by western-blot analysis (fig. 1a).",pmc5723691,1,10,11,1,21
pi3k,protein,,pik3ca,uniprot,q05234,plasma membrane,go:0005886,src,protein,,src,uniprot,q05234,plasma membrane,go:0005886,negative,d,inhibition,,,,,human,['115'],nan,nan,a reduction in pi3k pathway signaling correlates with sensitivity to the combined inhibition of src and the mapk pathway,pmc5833015,1,10,11,1,21
braf,protein,,braf,uniprot,p00722,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,q05524,plasma membrane,go:0005886,positive,d,phosphorylation,,8505c,adenocarcinoma,,human,['41'],nan,nan,"eleven human thyroid cancer-derived cell lines were grown in 10% fbs medium and studied for mek and erk activation: two cell lines without known mapk pathway genetic alteration, one with a ret/ptc rearrangement, two with a ras activating point mutation, and five with the brafv600e mutation. protein expression levels were assayed by immunoblot for the brafv600e mutation, phosphorylated mek (p-mek), total mek1 (t-mek1), phosphorylated erk (p-erk), total erk (t-erk) and gapdh. graphs represent subsequent quantification of p-mek/t-mek1 and p-erk/t-erk ratios. the black star on the upper graph indicates that the quantification of p-mek/t-mek1 was not done in the hth74 cell line due to the loss of t-mek1 expression. however, mek2 expression was secondary assessed and is preserved explaining the p-mek band (data not shown).",pmc5599027,1,10,9,1,19
braf,protein,,braf,uniprot,p00398,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,q03839,plasma membrane,go:0005886,positive,d,phosphorylation,,,b-cell,,vein,['174'],nan,nan,"while braf inhibitors of both classes stimulate the formation of braf-craf dimers [89,138], type-ii inhibitors are considerably less efficient than type-i inhibitors in stimulating the phosphorylation of downstream targets, i.e., of mek kinases and, henceforth, in activating the mapk pathway. among the possible explanations of this phenomenon, the one that is getting progressively increasing credit is that braf molecules locked in the dfg-out conformation by type-ii inhibitors have poor efficiency in transactivating the kinase activity of the partner protomer [48,135,138,139]. interestingly, type-ii kinase inhibitors are directed toward the most divergent regions among the various kinases, thus having the additional potential advantage of exerting a highly selective, target-specific action. based on previous considerations, type-ii inhibitors should have greater potential than type-i inhibitors in maximizing braf inhibition as single agents or in combined therapies for melanoma treatment. unfortunately, first generation type-ii inhibitors did not hold up to the promises, at least for melanoma treatment.",pmc6472057,1,10,9,1,19
braf,protein,,braf,uniprot,q02533,plasma membrane,go:0005886,mek,protein,,mek1,uniprot,p00775,plasma membrane,go:0005886,positive,d,dimerization,,,b-cell,,vein,['75'],nan,nan,"surprisingly, other mutations were found to render braf inactive (davies et al., 2002). the biochemical analysis of these “kinase-impaired” mutations revealed that although they reduce braf's enzymatic activity, braf still activates mek through dimerization with craf in a ras dependent manner (wan et al., 2004; garnett et al., 2005). confirming earlier studies (weber et al., 2001), it is now well established that raf kinases homo and hetero-dimerize partly in a ras dependent manner. importantly, these interactions can impact on the response to inhibitors of braf. thereby, inhibitor-binding triggers dimerization and in the presence of (hyper)-active ras, instead of pathway-inhibition, this leads to the so called “paradoxical” pathway-activation through craf (wan et al., 2004; garnett et al., 2005; hatzivassiliou et al., 2010; heidorn et al., 2010; poulikakos et al., 2011). elucidation of this complex mechanism has proven valuable in the understanding of some of the side effects that braf inhibitors produce in patients (see below).",pmc4846800,1,10,9,1,19
braf,protein,,braf,uniprot,p13547,cytoplasm,go:0005634,mek,protein,,mek1,uniprot,p00155,cytoplasm,go:0005634,positive,d,activates,,,,,human,['76'],nan,nan,"in parallel, inhibitors targeting mek (e.g., selumetinib, trametinib, cobimetinib) have been developed. braf's unique effector is mek, and pre-clinical studies have shown that braf mutant cells are significantly more sensitive to mek inhibition inhibitors than ras mutant cells (solit et al., 2006), probably due to ras activating other pathways such as the pi3k-cascade to promote cell survival (haass et al., 2008). despite drug related toxicities limiting the use of mek inhibitors, recently developed highly potent inhibitors show efficacy in patients (flaherty et al., 2012; kirkwood et al., 2012; ascierto et al., 2013).",pmc4846800,1,10,1,1,11
mek,protein,,map2k1,uniprot,q96787,cytoplasm,go:0005736,erk,protein,,mapk3,uniprot,p00432,cytoplasm,go:0005736,positive,d,inhibition,,,,,human,['88'],nan,nan,"an alternative combination that is currently in clinical trials is the combined inhibition of mek and erk (nct02457793). the rationale behind this combination is the notion that resistance to targeted inhibition of raf and mek often involves reactivation of erk (ryan et al., 2015), while suboptimal suppression of erk activity in raf mutant cancers may underlie the limited efficacy (bollag et al., 2010; corcoran et al., 2015). although our ras mutant crc organoids showed sensitivity to dual inhibition of mek and erk, also this drug combination induced cell-cycle arrest rather than cell death, questioning whether it will be sufficient for the treatment of ras mutant crc.",pmc5127645,1,10,1,1,11
